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Resumo 
Helicobacter pylori (H. pylori) é uma bacteria espiralada que cresce e reveste o interior do 
estômago humano. A adesão desta bactéria ao epitélio gástrico facilita o processo inicial de 
colonização, a persistência da infecção e a libertação de factores de virulência para as células 
epiteliais hospedeiras. A infecção com H. pylori é comum nos humanos e, apesar de não causar 
enfermidades na maioria das pessoas afectadas, representa um grande factor de risco para o 
aparecimento de úlceras pépticas. Estudos nesta área têm provado que a colonização do estômago 
com H. pylori é uma importante causa de cancro gástrico, o qual corresponde à terceira maior 
causa de morte por cancro a nível mundial.  
Apesar do uso de tratamentos com base em antibióticos para combater a infecção por H. 
pylori, a sua eficácia tem sofrido uma redução, dado o aumento de resistência da bactéria e estas 
substâncias. Por este motivo, tornar-se imperativo o desenvolvimento de novos estudos, na 
tentativa de combater este problema, usando métodos alternativos aos actualmente estabelecidos. 
Uma vez que o processo de colonização de H. pylori está dependente da interacção de 
diferentes adesinas bacterianas com glicanos expressos pela mucosa gástrica, o estudo destas 
interacções demonstra grande interesse. Em particular, um grande número de estirpes adere à 
mucosa gástrica usando a blood group antigen-binding adhesin (BabA), que se liga especificamente a 
receptores Lewis b (Leb). 
Tendo isto em conta, o estudo proposto foi motivado por dois objectivos principais. Acima de 
tudo, esta investigação teve como objectivo determinar os parâmetros experimentais necessários 
para estabelecer um modelo de infecção por H. pylori, usando um modelo animal com expressão de 
Leb e uma estirpe de bactéria BabA positiva. Em paralelo, o estudo de micropartículas de quitosano 
(Ch Mics) como um possível tratamento para a infecção foi também desenvolvido, avaliando a 
citotoxicidade destas partículas in vitro e testando in vivo a sua capacidade de erradicar a bactéria 
do estômago dos animais. 
O modelo de infecção por H. pylori estabelecido, usando murganhos C57BL/6 demonstrou que a 
inoculação de 1x1010 CFU/mL (0.2mL; 3 inoculações numa semana) da estirpe BabA positiva B128 em 
Brucella broth, isolada de um murganho infectado, foi capaz de infectar 5 de 6 animais com 
1.55x104 a 1.01x105 CFU/estômago (2.13x102 CFU/g a 2.36x103 CFU/g). 
Relativamente ao tratamento da infecção por H. pylori (estirpe SS1), usando Ch Mics, a 
concentração de 10 000 Mics/animal (que revelou não ser citotóxica para células gástricas MKN45) 
não provou ser capaz de reduzir a infecção e, por este motivo, estudos adicionais devem ser 
realizados.  
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Abstract 
Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that grows and coats the inside of 
the human stomach. Adherence of this bacterium to the gastric epithelium facilitates initial 
colonization, persistence of infection and delivery of virulence factors to host epithelial cells. An 
infection with H. pylori is widely common in humans worldwide and, although most infected people 
do not develop disease, these bacteria mediate carcinogenesis and constitute a major risk factor for 
peptic ulcer disease. In fact, studies in this field have come to prove that colonization of the 
stomach with H. pylori is an important cause of gastric cancer, which corresponds to the third 
leading cause of cancer death worldwide.  
Despite the use of standard antibiotic treatments to fight H. pylori infection, their efficacy is 
progressively being reduced, given the growing resistance of bacteria to these substances. 
Therefore, it becomes imperative to develop new studies to fight this problem, using different 
approaches. 
Since the process of colonization of H. pylori relies on the interaction of different bacterial 
adhesins with glycans expressed by the gastric mucosa, the study of these interactions arouses 
potential means to find new treatments. Particularly, the blood group antigen-binding adhesin 
(BabA) and its specific binding to Lewis b (Leb) blood group antigens, is of great interest, as 
adherence of most strains relies on this interaction.  
Having this in mind, the proposed study was driven by two main goals. Most importantly, it was 
intended to determine the experimental parameters to establish an H. pylori infection model, using 
an animal model that expresses Leb blood group antigens and a BabA positive H. pylori strain. In 
parallel, the study of chitosan microparticles (Ch Mics) as a treatment of H. pylori infection was 
developed, assessing their toxicity in vitro and evaluating in vivo their capacity to eradicate these 
bacteria from mice stomach, by oral administration of the particles.  
The proposed study enabled the establishment of an H. pylori infection model, using C57BL/6 
mice, and revealed that B128 strain (BabA positive), isolated from an infected mouse and 
inoculated with 1x1010 CFU/mL (0.2mL; 3 inoculations in one week) to the animals, using Brucella 
broth as the administration vehicle, was able to successfully infect 5 out of 6 animals, with 1.55x104 
to 1.01x105 CFU/stomach (2.13x102 to 2.36x103 CFU/g). 
Regarding the treatment of H. pylori infection (with SS1 H. pylori strain) using Ch Mics, a 
concentration of 10 000 Mics/mice (found non-cytotoxic to MKN45 cells) did not prove to be able to 
reduce this infection and, so, further research needs to be performed on this topic. 
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Chapter 1 
Literature Review 
 In this chapter, some important concepts are explored to further understand the 
subject of this study and to consolidate some aspects concerning it.  
 First, the anatomical and physiological features of the stomach are considered, since 
this organ is the central point of this investigation.  
To better understand the infection by H. pylori and the way this bacterium interacts 
with the stomach, the following sections include its description. Information about the 
available treatments nowadays and its benefits and drawbacks are also explored in this 
chapter. Furthermore, still taking into consideration the infection by H. pylori, in vivo 
models are established in order to carry out research studies and so, these are also 
regarded here, considering its evolution over the years and the differences between 
animals tested and humans. A summary of the most suitable parameters to establish an H. 
pylori infection model, with regard to the interaction between BabA adhesins and Leb 
antigens is also presented. 
Finally, the use of chitosan as a biomaterial is explored, with reference to its 
chemical structure, along with the most relevant properties for this work and, 
particularly, to its application as microparticles. 
1.1. Anatomical and Physiological Considerations 
 The digestive system has a crucial role in providing nutrition to the cells that form the 
body, maintaining, along with the circulatory system, the supply of water, electrolytes and 
nutrients, indispensable to the survival of these fundamental biological units [1]. 
  
Literature Review 
 
2 
 
 Essentially, two groups of organs form the digestive system: the gastrointestinal tract, 
also known as alimentary canal, and the accessory digestive organs. Particularly, the 
stomach belongs to the first mentioned group and its primary function is to store the food 
ingested during a meal, as well as to regulate its release into the duodenum (first section 
of the small intestine). It is a highly vascular distensible sac-like organ that holds food and 
starts to digest it by secreting gastric juice. Protein digestion is, therefore, initiated by 
this organ and is responsible for denaturing dietary proteins, a role played by digestive 
enzymes and, in particular, by hydrochloric acid (HCl), which, apart from maintaining the 
acid pH of the stomach (between 1 and 3), activates pepsin and lingual lipase, breaking up 
connective tissues and plant cell walls present in the food ingested. Both food and gastric 
juice are mixed with the help of peristaltic movements (performed by the muscle tissue 
present in this organ), producing a semifluid acid mass, known as chime [1-6].  
 Anatomically, the human stomach is located in the upper quadrant of the abdomen 
and can be divided into 4 distinct regions (Figure 1): cardia, fundus, corpus (body and 
antrum) and pyloric region. This latter includes the pyloric sphincter, responsible for 
regulating the passage of chime into the duodenum [6].  
 Regarding its microscopic anatomy (Figure 1), the stomach contains five wall layers, 
where the innermost, responsible for producing stomach acid and digestive enzymes, is 
called mucosa and is covered by simple columnar epithelial cells. The depressions in 
gastric mucosa are called gastric pits (also known as foveolae), which flatten when 
stomach is full, but form longitudinal wrinkles when empty. They are indentations in the 
stomach that denote entrances to the tubular shaped gastric glands, in charge of 
producing gastric juice. The subsequent layer is submucosa and, outside this, a thick layer 
of muscle is found (muscularis propria), allowing the stomach to move and mix its 
contents. Finally, the outermost layers are called subserosa and serosa, which wrap the 
stomach. [1, 3, 6]. 
 
Figure 1. Gross and microscopic anatomy of the stomach. Retrieved from Encyclopedia Britannica, 
Inc. [7]. 
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 In particular, the mucous layer that protects the mucosa against acid, proteolytic 
enzymes and mechanical damage consists of a polymeric matrix formed by high-molecular 
mass oligomeric glycoproteins, called mucins. The most representative mucins present in 
the stomach are MUC5AC and MUC6, produced by the surface epithelium and the gastric 
glands, respectively. This mucin distribution determines the gastric glycosylation pattern 
since expression of MUC5AC is accompanied by similar distribution of fucosyltransferases, 
leading to co-expression of type 1 Lewis a and Lewis b blood group antigens, while MUC6 
expression is associated with the type 2 Lewis x and Lewis y antigens [8, 9]. Particularly, 
Lewis b is naturally expressed in the human gastric surface mucosa in the majority of cases 
[10, 11]. 
 Due to its intrinsic properties, the stomach is protected from the acidic and 
enzymatic environment it creates. As already mentioned, the presence of a thick, alkaline 
mucous is able to resist action of acid and enzymes. Besides, the fact that epithelial cells 
are separated from each other by tight junctions prevents gastric juice to pass between 
them and, thus, to destroy the connective tissue. Finally, the epithelial cells are 
constantly being replaced, living only 3 to 6 days. Failures in these protective measures 
can result in inflammation and peptic ulcer disease [6]. 
1.2. H. pylori  
 H. pylori is one of the most common bacterial pathogens of humans and it is mainly 
found in the mucosa layer, where it grows and coats the inside of the stomach. This Gram-
negative spiral-shaped bacterium is 2-5 µm long and 0.5-1 µm wide and is microaerophilic, 
presenting high survival success in the stomach due to its adaptable mechanisms [12-17]. It 
is able to survive in the acidic conditions of this organ, secreting an enzyme (urease) that 
converts the chemical urea to ammonia, a substance responsible for neutralizing the acidic 
environment. This causes the mucin to liquefy, which, together with bacteria’s helical 
shape and the presence of flagella movement, allows H. pylori to swim through it and 
burrow into the mucous layer (Figure 2), less acidic than the human stomach.  
 
Figure 2. H. pylori crossing the mucus layer of the stomach. Adapted 
from Bansil, R. et. al. (Credits: Zina Deretsky) [18] 
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H. pylori is successful in persisting in this organ also because immune cells are unable to 
reach its lining, failing to recognize it and eliminate it. Adherence of H. pylori to the 
gastric epithelium facilitates, thus, initial colonization, persistence of infection and 
delivery of virulence factors to host epithelial cells [13-16, 19]. The colonizing H. pylori 
adhere to gastric epithelium by different bacterial adhesins and bind to glycans 
(fucosylated ABO blood group antigens, glycans with charged modifications such as sialic 
acid and sulfate, and also unsubstituted core chain glycans), present in the stomach, as 
receptors [20]. In other words, the adaptation of H. pylori to the gastric environment 
relies on the binding to glycoconjugates that work as receptors or binding epitopes for 
establishing the infection [10]. Overall, mucosal adherence of this bacterium is dependent 
on a different range of attachment proteins, known as adhesins. The best characterized 
interaction is between the blood group antigen-binding adhesin (BabA; protein of 78kDa, 
encoded by babA2 gene [21]) and the ABO blood group and Leb antigens [20, 22-25]. In 
addition, the sialic acid-binding adhesin (SabA) mediates the adherence of H. pylori to 
inflamed gastric mucosa by binding sialylated carbohydrate structures such as sialyl-Lewis 
x and sialyl-Lewis a. LabA (LacdiNAc binding adhesin), in turn, binds LacdiNAc motifs [10]. 
Localization of this LabA target, restricted to the gastric mucosa, suggests a plausible 
explanation for the tissue tropism of H. pylori [26]. Moreover, bacterial virulence factors 
such as the cytotoxin-associated gene A (CagA) pathogenicity island-encoded protein and 
the vacuolating cytotoxin A (VacA), present in some H. pylori strains, are also reported to 
help in the colonization of the gastric mucosa and to modulate the immune response of 
the host [19].  
 The process of colonization induces chronic gastric inflammation, due to a high 
production of urease that increases the pH and activates host immune response, which can 
progress to a variety of diseases, ranging in severity, from superficial gastritis and peptic 
ulcer to gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma (Figure 
3)[12, 27].  
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Figure 3. Schematic representation of disease outcomes in H. pylori infection. NSAID – 
nonsteroidal anti-inflammatory drug; PPI - Proton pump inhibitor. Retrieved from Kusters, J. 
G., et al. [19].  
 Furthermore, the virulence factors of H. pylori and the effects that these trigger are 
presented in Table I, to better understand its action in the human body. 
 Unlike other bacterial pathogens, H. pylori is genetically heterogeneous, suggesting 
low clonality. This implies that different H. pylori-positive subjects may carry distinct 
strains of this bacterium. Thus, clinical H. pylori strains are highly diverse both in their 
genetic information and potential to induce pathogenicity [28]. This diversity might be 
associated with H. pylori’s adaptation mechanisms to the gastric conditions and the 
patterns of the host-mediated immune response [19].   
 Changes in the conformation of H. pylori from a spiral shape to a coccoid form are 
reported to be caused by aging or exposure to unfavorable conditions (nutrient starvation 
or media containing growth inhibitors) and so, this might be an indication that bacteria are 
either deceased or in a dormant state [29-31]. Thus, during infection, mostly spiral-shaped 
H. pylori bacilli are found in the gastric mucosa of the hosts, despite the presence of some 
coccoid forms [30]. 
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Table I. H. pylori: virulence factors and their effects. Adapted from Wang, X. [12]. 
Bacterial properties Virulence factors Effects/properties 
Colonizing Flagella Active movements through mucin 
 Urease Neutralization of gastric acid 
 Adhesins Anchoring H. pylori to the epithelium 
Tissue damaging Proteolytic enzymes Glucosulfatase degrades mucin 
 120-kDa Cytotoxin-associated gene A 
(CagA) 
Related to ulcer and severe gastritis 
 Vacuolating cytotoxin A (VacA) Damage of the epithelium 
 Urease Toxic effect on epithelial cells, 
disrupting cell tight junctions 
 Neutrophil activating protein Lead to neutrophil-mediated mucosal 
injury 
 Phospholipase A Digest phospholipids in cell membranes 
 Alcohol dehydrogenase Gastric mucosal injury 
Survival Intracellular surveillance Prevent killing in phagocytes 
 Superoxide dismutase Prevent phagocytosis and killing 
 Catalase Prevent phagocytosis and killing 
 Coccoid forms Dormant form 
 Heat shock proteins Sheathing antigen 
 Urease Prevent phagocytosis 
Other Lipopolysaccharide Low biological activity 
 Lewis x/y blood group homology Autoimmunity 
 
Isolated H. pylori strains have been classified as type I strains (highly virulent), 
intermediate strains or type II strains (reduced virulence) [32]. Particularly, some studies 
reveal that patients infected with H. pylori strains expressing BabA are more likely to 
present severe gastric diseases such as peptic ulcer and gastric adenocarcinoma, especially 
if they also present the VacA s1/m1 genotype and the cytotoxin-associated antigen (CagA) 
[22, 33-36].  Thus, apart from bacterial toxins, the adherence factors of each strain also 
contribute to the pathogenicity of H. pylori [37]. The expression of CagA, VacA and BabA 
in different H. pylori strains that infect humans is presented in Table II. 
With this in mind, when developing an animal model to study infection by this 
bacterium, it is important to choose the adequate strain, as the capacity of H. pylori 
strains to colonize different animals is both bacterial strain and host dependent [12].  
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Table II. Expression profiles of BabA, CagA and VacA activity in H. pylori 
strains found in humans. Adapted from Tummuru et al., Henning et al., 
McClain et al. and Magalhães et al. [38-41]. 
H. pylori strain BabA CagA VacAa,b 
J99 + + s1b/m1 
J87; J116; J123; J133; J258 + + NA 
J104; J128; J166; J178; J223  - + NA 
J63; J154; J195 - - NA 
J190; J262 + - NA 
86-313; 86-338 - - - 
87-33; 87-29; 87-81; 87-91; 87-199  + + + 
87-203 + - - 
87-75; 87-230 - - - 
92-18; 92-25; 92-26; 92-27 + + + 
92-19; 92-21 - + + 
92-20; 92-23; 92-28 - - - 
92-29 - + NA 
26695 - + s1a/m1 
60190 - + + 
Tx30a - - - 
17875/Leb + NA NA 
17875babA1A2 - NA NA 
avacA gene is present in all strains, however, the secretion of VacA does 
not always occur, this being dependent on the vacA genotype (signal 
region alleles: s1a, s1b and s1c or s2; middle region alleles: m1 or m2) 
[36, 42]. 
b (+) and (-) symbols were attributed to the bacteria strain, when 
vacuolating-cytotoxin activity was reported to be present or absent, 
respectively, but no information about vacA genotype was found. 
NA Information not available.  
1.3. Available treatments for H. pylori infection 
The treatment of H. pylori is subject of great attention, given the constant need to 
eliminate these bacteria from the human stomach and to prevent potentially severe 
consequences of its expansion in this organ. Taking this into consideration, different 
perspectives to eradicate this pathogen have been considered and implemented in clinical 
practice over the years.  
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 The first applied treatments were based on monotherapies using, thus, an unique 
compound to fight H. pylori infection, with clarithromycin being the most effective single 
drug. However, despite allowing an eradication rate close to 40%, this was still considered 
a low efficacy treatment, which led to the emergence of dual therapies. These, in turn, 
corresponded to the administration of a proton pump inhibitor (PPI) combined with 
amoxicillin. This second approach is still in practice in some countries, but it has mainly 
been replaced by triple therapies, a combination of two antibiotics and a PPI or a bismuth 
compound. Overall, the main drugs used in these therapies include tetracycline, 
amoxicillin, imidazoles (predominantly metronidazole and tinidazole) and macrolides (in 
particular clarithromycin) [19]. 
Nowadays, PPI-based triple therapy is considered the first-line treatment for H. pylori 
infection, being the standard approach a combination of PPI, amoxicillin and 
clarithromycin or metronidazole, accordingly to the Maastricht Consensus Report IV [43]. 
However, since first-line therapy fails in approximately 20% of patients, there is the need 
for second-line and even third-line approaches that imply the use of regimens with an 
improved performance against antibiotic-resistant H. pylori strains [43-47].  
Although the knowledge of the pathogenesis of gastric neoplasms is increasing and 
new approaches to the prevention of gastric cancer by eradication of H. pylori infection 
are being investigated, this disease is still the third leading cause of cancer death in both 
genders worldwide (723,000 deaths, 8.8% of the total) [48], with antibiotic resistance 
being a growing problem. This might be associated with the antibiotic degradation in the 
acidic environment of the gastric lumen or to its poor penetration that leads to sub-
bactericidal concentration of antibiotics in infection site, unable to successfully eliminate 
this pathogen [49].  
In regards to future therapies, as an attempt to overcome this problem, efforts 
towards the elucidation of the molecular and genomic structure of H. pylori will help to 
identify specific molecules that represent potential targets for developing new antibiotics 
[44, 50]. Vaccination is another valuable approach that is gradually being considered a 
mean to control H. pylori and its associated morbidity [44, 47, 51]. However, further 
research needs to be performed before this can become an option in clinical practice [44, 
49]. Moreover, the use of Ch nano and microparticles is increasingly being sought as an 
innovative approach to deliver the necessary compounds for the elimination of H. pylori 
from infected patients, by encapsulation of several antibiotics [49]. This provides, thus, 
local and controlled delivery at the infection site by encapsulation of conventional 
antibiotics, protecting them from enzymatic and acidic degradation [49]. Besides, the use 
of these microparticles as binding agents of H. pylori urease, flagella, adhesins, etc., is 
also revealing their ability to inhibit, kill or remove this bacterium from the stomach, 
particularly if target molecules towards H. pylori, such as fucose or carbohydrates 
(namely, Leb or sialyl-Lewis x), are incorporated [10, 49, 52]. This strategy has been 
  
1.4. In vivo models  
 
9 
 
pursued by our group [10] and involved the development of Ch microparticles, chemically 
modified with glycans (GlyRs, also known as glycan receptors) (Lewis b and sialyl-Lewis x) 
[52, 53]. In the referred study, the specificity of the referred adhesin-glycan interactions 
was evaluated both in vitro (using Leb positive gastric mucosa sections from human and 
mice) and ex vivo (resorting to mice fresh stomach samples), revealing that the 
immobilization of Leb increases the affinity of H. pylori towards the microparticles, 
replacing gastric mucosa with similar carbohydrates [10]. Previously, Parreira et al. [54] 
have already proven that these same immobilized GlyRs (Leb and Lewis x) onto 
bioengineered surfaces (self-assembled monolayers - SAMs) were able to specifically 
interact with the correspondent adhesins present in H. pylori, revealing, once again, the 
specificity of the interaction between Leb receptors and BabA adhesins. 
As studies in the field of biomedical engineering and pharmacogenomics evolve, new 
approaches are being discovered, always with the concern of guarantying complete 
therapeutic efficacy in the process of eradication of H. pylori. Markedly, the above 
mentioned Ch microparticles with glycan receptors constitute a promising approach to 
study H. pylori infection. Therefore, further research concerning this strategy should be 
followed, with the establishment of infection models to better understand the underlying 
mechanisms that contribute to the survival of this bacterium in the stomach.  
1.4. In vivo models 
 Understanding the factors involved in H. pylori infection is crucial for the recognition 
of the role of these bacteria in the etiology of upper gastrointestinal pathology [19]. With 
this in mind, H. pylori infection models have long been established and different animals 
have been challenged to try to mimic this process seemingly with what happens in 
humans, always with the goal of finding new strategies to eradicate these bacteria from 
the stomach.  
 The first attempts in this area were performed in laboratory animals, such as mice, 
rats and rabbits, but rather unsuccessfully, due to limitations in technological advances by 
that time. Therefore, alternatively, models using naturally infected animals (ferrets and 
non-human primates) or also gnotobiotic dogs and piglets were used [12, 55].  
 With the increasing knowledge and experience in this area, experiments with 
Mongolian gerbils, guinea pigs, cats and macaque monkeys have also been performed. 
Particularly, the longer life span of gerbils, when compared to mice and the larger amount 
of gastric tissue available for histologic examination represents important advantages [56]. 
However, on the basis of cost and availability of immunological reagents and genome 
information, mouse is, nowadays, considered to be the most convenient and appropriate 
animal model to use [12, 55].  
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 It is crucial, though, to keep in mind that, despite the undeniable value of using 
animals as H. pylori infection models, the results obtained in these experiments cannot be 
fully extrapolated to humans. Despite the basic structural similarities, the gross 
morphology of the mammalian stomach presents some differences across species. In fact, 
the stomach morphology is greatly influenced by adaptation mechanisms, frequency and 
type of food ingested, animal size, among various other aspects [19, 57].  
 Particularly, comparing the anatomy and histology of mice and human stomach, some 
differences can be found and these are described in Table III. 
 
 
Table III. Comparative anatomy and histology of mice and human stomach. Retrieved from Treuting, P. 
M. et al. [58] 
 
 As illustrated in Figure 4, the stomach of mice is divided into two distinct regions, the 
non-glandular forestomach and the glandular stomach, separated by a limiting ridge. The 
demarcation between the two areas is easily identified, as the non-glandular area has 
keratinized epithelium, similarly to the esophagus [59]. For most investigators, the region 
of interest is precisely the corpus and the adjacent segments, as it presents more 
similarities with the human stomach [19, 60].  
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Figure 4. Mice: gross anatomy of the stomach. 
 Histologically, differences between mice and human’s stomach can also be denoted 
(Figure 5.). Once again, whereas mice have a limiting ridge (Figure 5 (I)), humans have the 
esophageal Z-line (Figure 5 (II)) that links the esophagus with the cardiac region of the 
stomach. The fundic region, on the other hand, is similar to both, with the presence of 
gastric pits, parietal and chief cells. Particularly, in mice, their fundic region is the largest 
portion of the glandular stomach and cardiac region (Figure 5 (V)) is the smallest. In this 
latter region often mild inflammation can be found, which can be aggravated by the 
presence of certain diseases and as animals age [58].   
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Figure 5. Histomorphology of mice (left column) and human (right column) stomach. (I) 
Mouse gastric limiting ridge (margo plicatus); (II) Human Z-line line (junction of the esophagus 
with the cardia of the stomach); (III) Mouse fundic mucosa; (IV) Human fundic mucosa; (V) 
Mouse cardia. F Foveolar columnar mucus-secreting cells, P Parietal cells, GP Gastric pits, C 
Chief cells. Arrows point to chief cells. Adapted from Treuting, P. M. et al. [58]. 
 
 Notwithstanding, the use of in vivo animal models to study human diseases has greatly 
contributed to improvements in medicine and it is an important first step before moving to 
human trials and to clinical practice. 
1.4.1. H. pylori infection models 
 When using animal models, it is crucial to determine specific parameters to establish 
H. pylori infection. First of all, it is necessary to choose an adequate bacterial strain for 
the inoculation, in order to meet the requirements of the investigation. Hereupon growth 
I 
III 
II 
IV 
V 
Cardiac region 
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conditions used for the preparation of inoculum should be set, ensuring that the majority 
of bacteria are motile and spiral-shaped, prior to inoculation.  
 Since H. pylori is microaerophilic, these have to be grown in jars (with gas-generation 
kits or a standard microaerobic atmosphere), CO2 incubators or anaerobic chambers with a 
microaerobic atmosphere [21]. Regarding the culture media, bacteria can be grown either 
in liquid or on solid media [61, 62], but it is reported that these grow slowly in liquid 
environment, with formation of a high number of coccoid forms [21]. For that reason, 
generally, solid medium is preferred. Particularly, H. pylori seems to grow more and with 
larger colonies on solid media containing blood or blood products, such as 10% horse blood 
agar plates and 7% lysed horse blood agar plates [21]. Columbia agar, Brucella agar and 
brain heart infusion agar are also commonly used solid media [31, 63]. Notwithstanding, H. 
pylori is also described to be grown in brain heart infusion, Brucella broth (BBL), Mueller-
Hinton broth or tryptone soya broth, all liquid media [63]. 
Regarding the choice of animal model to establish H. pylori infection an extensive 
number of studies involving H. pylori culture have already been reported as an attempt to 
establish in vivo infection models. The most widely used animals are mice, namely BALB/c 
and C57BC/6 strains, and also Mongolian gerbils (Meriones unguiculatus) [35, 56, 61, 64-
70]. Apart from the animals referred, studies on DBA/2, CH3, SJL and NMRI mice have also 
been reported, but with rather unsuccessful level of colonization in most regions of the 
stomach. Furthermore, FVB/N Leb-expressing transgenic mice are also reported as 
potential models for studying H. pylori infection, given the production of Leb antigens 
found in the gastric pits and surface mucous cells [71, 72]. However, studies using this 
animal focus specifically on the establishment of adhesion models [72, 73] and so, further 
research needs to be performed before FVB/N Leb-expressing transgenic mice can become 
an H. pylori infection model [74]. 
 To develop H. pylori infection, the number and size of the inoculum doses should also 
be set. For mouse-adapted H. pylori strains, as it is the case of SS1 strain, one inoculation 
(106 - 108 CFU/mouse) is generally sufficient, while other strains may require more 
inoculations (up to three) [62, 75]. The choice of the animal species and strain is equally 
important for the course of the investigation. In the particular case of mice, it is reported 
that C57BL/6 are more susceptible to infection than BALB/c animals. The remaining 
aspects include the determination of the vehicle for the inoculation of the bacteria, the 
euthanasia time-point to establish infection and the methods for the detection of H. 
pylori infection [19, 61, 62]. For most studies, the presence of H. pylori is best detected 1 
month after inoculations [62]. 
An overview of the conditions established on some of these studies, with regards to 
the most common tested animals mentioned, namely Mongolian gerbils, BALB/c mice and 
C57BL/6 mice is presented in Tables IV, V and VI, respectively. 
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Table IV. Main specific parameters reported to establish H. pylori infection in Mongolian gerbils. 
Bacteria strain B127, B129a 
[56] 
B128a  
  [56, 64] 
SW18, B102, B108, 
B120b [56] 
TN2GF4 
 [70] 
Bacterial concentration (CFU/mL) 109 - 1010 109 - 1010 108 
Vehicle BBL BBL BBL supplemented 
with 2.5% heat-
inactivated FBS 
Nº inoculations 3x (days 0, 2, 4)  3x  
(days 0, 2, 4)  
1x 
Inoculations volume (mL) 0.8 - 1.0 0.8 - 1.0 1.0 
Time to develop infection (weeks) 2 - 4 NA 6 
Infection efficiency HA: 93% - 100% animals 
infected 
HA: 23% animals 
infected 
CFU’s counting 
(CFU/stomach): 
10
5
 
a cagA+ strains 
b cagA- strains  
NA Information not available. 
HA Histological analysis; CFU Colony-forming units; BBL Brucella broth; FBS Fetal Bovine Serum. 
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Table V. Main specific parameters reported to establish H. pylori infection in BALB/c mice. 
Bacteria strain Human samplea  Human 
sampleb [35] 
    SS1 
 [65] [76] [77]  [61] [77] 
Bacterial concentration (CFU/mL) 108 109 0.8 × 109      109 
Vehicle BBL BBL 
supplemented 
with 2% FBS 
BHI Peptone 
water 
Nº inoculations 2x 
(consecutive 
days)  
3x (2 day 
interval)  
3x 
(consecutive 
days) 
3x (5 day 
period) 
1x 
Inoculations volume (mL) 1.0 0.1 0.8     0.1 
Time to develop infection (weeks) 2 – 3  NA 4 ≈ 8 NA 4 
Infection efficiency HA: 18%-30% 
infected 
animals 
NA HA: 81,3% 
infected 
animals 
CFU’s counting  
(CFU/g tissue):  
10
3
 – 106 10
4
 - 10
6
 
a Clinical isolate of H. pylori obtained from a patient with several gastric ulcers.  
b Clinical isolate of H. pylori obtained from a patient with several duodenal ulcers. 
NA  Information not available.   
HA Histological analysis; CFU Colony-forming units; BBL Brucella broth; FBS Fetal Bovine Serum; BHI Brain Heart 
Infusion broth. 
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Table VI. Main specific parameters reported to establish H. pylori infection in C57BL/6 mice. 
Bacteria strain SS1  Human samplea B128 
 [61] [66] [68] [77] [75] [78] [76] [79]  [80] [81] 
Bacterial concentration 
(CFU/mL) 
109 107 108 10
9
 108 108 109 109 3 x 108 c 2 x 108 c 
Vehicle BHIb BBL Peptone water BBL NA Isosensitest 
broth 
NA NA 
Nº inoculations 3x  
(3 day 
period) 
3x  
(5 day 
period) 
1x 3x 
(1 day 
interval) 
3x  
(2 days 
interval) 
3x  
(1 day 
interval) 
2x  
(2 days 
interval) 
NA 
Inoculations volume (mL) 0.1 1.0 0.1 0.2 0.1 0.1 NA NA 
Time to develop infection 
(weeks) 
NA     4 NA NA 2 - 4 3 3 2 
Infection efficiency  CFU’s counting (CFU/g tissue):  CFU’s counting (CFU/stomach): 
 10
3 – 106 NA  5 x 10
5
 10
4
 - 10
6
 NA NA NA 10
5
 – 4 x 10
5
 10
4 104 - 105 
a Clinical isolate of H. pylori obtained from a patient with several gastric ulcers.  
b In some cases [66] supplemented with 10% sheep blood, 5% horse serum, and Skirrow’s supplement. 
c Bacterial concentration in H. pylori cells/mice, instead of CFU/mL. 
NA – information not available. 
HA Histological analysis; CFU Colony-forming units; BBL Brucella broth; BHI Brain Heart Infusion. 
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Regarding the choice of the bacteria strain for inoculation, this is highly variable, but 
it is verified a preference for SS1 strain in murine infection models, regarding its 
adaptation features to these animals [61, 66, 68, 75, 77, 82, 83]. B128 strain, in turn, is 
widely applied on gerbils [56, 64], although studies with C57BL/6 refer its use [79-81]. 
Studies with C3H [84] and 129/SvJ mice [85] are also reported for infection development 
using B128 H. pylori strain.  
The commonly used method for inoculation of H. pylori in infection models is oral 
gavage, also known as orogastric inoculation [35, 56, 61, 64-70]. This corresponds to the 
administration of the bacteria suspension directly into the lower esophagus, introducing a 
feeding needle into the mouth [86]. Animals chosen for these studies are, generally, aged 
between 6 to 8 weeks old for both, mice and gerbils. In fact, the sexual maturity of mice 
is attained between these ages, while gerbils reach puberty at an earlier age (around 70–
84 days old). This suggests that, preferentially, young adults are chosen as infection 
models [87, 88].  
Regarding the administration of bacterial suspensions to the animals, its 
concentrations range between 107 and 109 CFU/mL for mice (C57BL/6 and BALB/c) and 
are, generally, higher for gerbils (109 - 1010 CFU/mL). The administration pattern varies 
between one and three inoculations, with volumes ranging from 0.1mL to 1.0mL. The 
solutions normally selected for the bacterial suspension (inoculation vehicle) are BBL, 
brain heart infusion (BHI) and peptone water, in some cases supplemented with fetal 
bovine serum. Finally, considering the time to develop infection, studies suggest that two 
to four weeks is sufficient to find colonizing units of H. pylori in gerbils and C57BL/6 mice, 
and two to eight weeks in BALB/c mice [35, 56, 61, 64-70]. Specifically for C57BL/6 mouse 
strain, several authors indicate that 1 month after infection, animals have a concentration 
of approximately 103 to 106 CFU/g tissue of H. pylori, if infected with the SS1 strain [61, 
68, 77, 82]. 
The application of the infection models is widely variable. Comparisons between 
different strains, specially, cagA-positive (B127, B128, B129 strains, etc.) and cagA-
negative (B102, B108, B120 strains, etc.) are a common approach to study H. pylori 
infection, indicating that this virulence factor might be associated with a higher 
pathogenicity of the bacteria. Similarly, studies analysing the role of VacA cytotoxin during 
colonization of H. pylori are also reported, suggesting that H. pylori strains expressing 
active alleles of vacA may be better adapted for host-to-host transmission [68]. In 
particular, severe pathology in mice is associated with the expression of this cytotoxin, 
along with CagA expression [77]. Furthermore, gastric pathology, including gastric cancer, 
is analyzed in the different animal models and comparisons across animal species and 
strains are regarded, with the goal of mimicking, as closely as possible, the infection by H. 
pylori in humans [62].  
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Generally, the common practice to analyze and interpret results from these animal 
tests includes the performance of histological analysis and CFU countings of the stomach 
to examine, qualitatively and quantitatively, the extend of H. pylori colonization and 
infection. Histology of the liver, kidney and spleen are also investigated to better 
understand the effects of H. pylori infection in animals [89]. With that purpose, 
hematoxylin and eosin (H&E) staining, Giemsa staining and Warthin-Silver staining are, 
generally, employed on sections of the organs under analysis. Hematoxylin is able to stain 
nucleic acids and, thus, the nuclei region, in a blue/purple color, whereas eosin’s pink 
color stains proteins non-specifically, revealing the cytoplasm and the extracellular matrix 
of the cells. Therefore, this technique allows the identification of different cell types and 
morphologies, including cancer-type specific patterns. Giemsa staining is characterized by 
colouring bacteria in blue/grey, with a background pink/pale blue. Nuclei are also 
coloured in blue [90]. The silver staining, in turn, deposits silver granules on some types of 
bacteria (comprising H. pylori), making them larger and more pronounced, which enhances 
its detection. It stains organisms in brown/black, giving the background a golden shade 
[91]. Apart from these, immunohistochemical staining (in this case, anti-H. pylori antibody 
immunostain) is also applied in most cases, relying on antibody-antigen interactions that 
may be valuable for the detection of certain cells expressing specific proteins of interest 
and, particularly, abnormal cells that might be associated with cancerous tumors [92, 93]. 
Furthermore, to confirm the presence of H. pylori, since urease, catalase and oxidase are 
produced by this bacterium, tests can also be performed to confirm their presence, based 
on these products [12, 19, 94]. Polymerase chain reaction (PCR) is, generally, used to 
characterize isolates of this bacterium and, so, to detect the genetic status of H. pylori 
[35, 61, 94].  
Reviewing the many studies developed in this area, it is possible to summarize the 
most adequate parameters to establish H. pylori infection for the study of the interactions 
between BabA adhesins and Leb receptors. This takes into consideration the ultimate goal 
of this investigation which consists in evaluating the efficiency of Leb-decorated 
microparticles in the eradication of H. pylori from the stomach. 
C57BL/6 mice seem to be more suitable H. pylori animal models, presenting higher 
colonization rates and similar pathological results as in human gastric experiments, if 
compared to BALB/c mice and Mongolian gerbils [66, 76, 77]. Furthermore, compared to 
other animals, it is known their advantages concerning costs, availability of immunological 
reagents and genome information, small size and reproducibility [95]. Most importantly, 
regarding the most widely studied animals for H. pylori infection (Mongolian gerbils, 
BALB/c and C57BL/6), this mouse strain has Leb receptors (Figure 6), which are absent 
from the gastric mucosa of gerbils [96]. Regarding BALB/c mice, no information referring 
to the presence of these antigens was found. Nevertheless, reports suggest that BALB/c 
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animals are less susceptible to infection than C57BL/6 mice, which, once again, makes the 
use of these latter a more interesting approach.  
 
Figure 6. Immunohistochemical staining of 
C57BL/6 mice gastric mucosa, using Lewis b 
recognizing antibodies (BG6). Magnification 200×. 
Adapted from Magalhães, et al. [40]. 
 
The choice of the bacteria strain should guarantee the expression of BabA adhesin. 
Focusing on this condition and according to Table II, there is a wide range of options 
available. However, the referred bacteria strains infect humans and, thus, adaptation to 
these animal models could be difficult. For that reason and assuming the choice of 
C57BL/6 mice, it is known that SS1 strain is adapted to these animals. However, this strain 
lacks the expression of BabA adhesin (unpublished work by our group), essential to the 
conduction of the investigation proposed. Hereupon, an analysis of the expression profiles 
of BabA, CagA and VacA of the different strains reported to infect Mongolian gerbils, 
BALB/c and C57BL/6 is presented in Table VII. Two of the strains revised were found to 
express BabA adhesin (B128 and TN2GF4) and so, either of them could be chosen to 
proceed the study. Particularly, TN2GF4 strain carries s1/m1 vacA genotype, which is 
associated with higher levels of pathogenicity [36]. 
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Table VII. Expression profiles of BabA, CagA and VacA in H. pylori strains found in Mongolian gerbils, 
BALB/c mice and C57BL/6 mice. 
Bacteria strain BabA CagA VacA 
B102 [56] NA - NA 
B108 [56]  NA - NA 
B120 [56] NA - NA 
B127 [56] NA + NA 
B128      + [unpublished work, 
Appendix A, Figure A1]  
      + [97]  s1a/m1 [97] 
 
B129 [56] NA + NA 
TN2GF4       + [96]       + [96] s1/m1 [98] 
SS1 [99, 100]  - 
[unpublished work] 
     - [99] s2/m2 [100] 
 NA – information not available. 
 
Once these two parameters are defined, the conditions to establish the infection can 
be analyzed. Generally, for a mouse-adapted strain, concentrations ranging from 107 to 
109 CFU/mL are able to establish infection in C57BL/6 mice after two to four weeks. The 
number of inoculations is reported to vary from one to three inoculations, with volumes 
that range from 0.1mL to 1.0mL. Notwithstanding, using B128 or TN2GF4 (not adapted to 
mice) might require some adaptations. Typically, H. pylori is administered in BBL, BHI or 
peptone water. A summary of the parameters selected can be found in Table VIII. 
The optimization of these conditions for the animal model and bacteria strain chosen 
may, eventually, enable the establishment of these infection model and constitute a 
valuable strategy to further explore the potential of Leb-decorated Ch microparticles to 
eradicate H. pylori from human’s stomach. 
Table VIII. H. pylori infection model parameters.  
Animal model C57BL/6 mice 
Bacteria strain B128 or TN2GF4 
Bacterial concentration (CFU/mL) 107 to 109 CFU/mL 
Vehicle BBL, BHI or peptone water 
Number of inoculations 1x – 3x 
Inoculations volume (mL) 0.1mL to 1.0mL 
Euthanasia time-point (weeks) 2 - 4 
1.5. Chitosan as a biomaterial 
Chitosan is an unique polymer with valuable physico-chemical properties allied to the 
ability to establish interactions with proteins, cells and living organisms [101]. In addition, 
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Ch can have a wide variety of shapes and structures with controlled composition, function 
and morphology, which reveals its versatility and great value, especially in biomedical and 
pharmaceutical formulations [102]. In these areas, the main chitosan-based biomaterial 
types include hydrogels, sponges, films, porous membranes and nano/microparticles. The 
application of these materials is mostly addressed to tissue replacements, drug delivery 
systems and wound dressing skin substitutes [101]. 
1.5.1. Chemical structure 
Chitosan results from the deacetylation of chitin, the primary structural polymer in 
the exoskeleton of crustaceans. This polymer is a linear, semi-crystalline polysaccharide, 
composed of repeating units of N-acetyl-D-glucosamine and D-glucosamine (Figure 7 (A)). 
The deacetylation degree (DA) of Ch indicates the number of amino groups present in the 
chain, corresponding to the ratio of D-glucosamines. Actually, if chitosan DA increases, the 
number of positive charges also increases [101]. This feature influences greatly the 
physical, chemical and biological properties of this polymer [101, 103, 104].  
Chitosan is soluble in dilute acidic conditions, where its molecular chains become 
protonated (soluble form: R-NH3) through the amino groups (Figure 7 (B)). Both the DA and 
the degree of protonation influence the antibacterial properties of Ch, particularly in 
acidic environment with a pH inferior to 6 [101, 102]. 
 
 
Figure 7. Chemical structure of (A) chitosan and (B) protonated 
chitosan. Adapted from Jiang, T., et al. [103]. 
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1.5.2. Properties 
Ch is a polymer with several peculiar and interesting properties, which include its 
non-toxicity, biodegradability and biocompatibility [49, 101, 103, 104]. In fact, the 
degradation of Ch results in the formation of non-toxic oligosaccharides that can be 
incorporated in metabolic pathways or further eliminated from the body. The degradation 
rate is dependent on the DA of chitosan [101].  
Most importantly, regarding the focus of this study, this polymer has been widely 
investigated in the treatment of H. pylori infection, being used for drug encapsulation 
systems and for bacterial binding, which results from its mucoadhesive and 
antimicrobial/binding properties, respectively [49]. The mucoadhesion of Ch is due to the 
interaction between chitosan’s positively charged amino groups and negatively charged 
gastric mucins [52, 105]. The presence of strong hydrogen bonding groups (-OH and -
COOH), the flexibility of the chain and the surface energy properties that favor spreading 
into the mucus are also reported to influence the mucoadhesive properties of chitosan 
[105]. In turn, its antibacterial properties result from the electrostatic interactions 
between the cationic Ch amino groups and the anions from the bacterial wall, being 
responsible for its intrinsic antibacterial activity and inhibiting proliferation of bacteria 
[53].  
Overall, chitosan derives from an abundant naturally occurring polymer, the chitin, 
gathering singular and valuable properties, with great pertinence in the field of biomedical 
engineering and health sciences.  
1.5.3. Chitosan microparticles 
In particular, the use of chitosan microparticles (Ch Mics) has been widely explored 
for pharmaceutical applications, being highly regarded as a drug delivery system. Its main 
function in these systems is to encapsulate drugs and allow its release into the stomach, 
increasing gastric retention time of the dosage forms and, therefore, allowing greater 
therapeutic benefits of the drugs. Allied to these, possible reduction of the frequency of 
administration and dose sizes may also be among the many advantages of using these 
particles. Most importantly, the versatility of microparticles takes advantage of its 
mucoadhesive properties, enabling the adhesion to multiple mucosal tissues, as it is the 
case of those found in the stomach [106]. Using innovative microencapsulation techniques, 
microparticles can be tailored into optimal drug delivery systems, with the desired release 
profile, by variation of copolymer ratio, molecular weight, as well as the DA of chitosan 
and the degree of crosslinking [52, 102]. 
More recently, another application of Ch Mics is under investigation, relying on the 
creation of an H. pylori binding system for the capture and removal of this bacterium from 
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the stomach. This might constitute a complement or even an alternative for standard 
therapy [52]. 
To produce these microparticles, different methodologies can be applied and these 
are schematized in Figure 8. Among them, ionic/ionotropic gelation using tripolyphosphate 
(TPP) for ionic-crosslinking and genipin for covalent crosslinking, are the most common 
approaches. Regarding the high solubility of Ch in acidic conditions, crosslinking is crucial 
to maintain the three dimensional structure of the microparticles in gastric fluids, mainly 
when developing binding systems with this polymer [49]. Particularly, TPP allows ionic 
interaction between its negatively charged counterion and the amino groups of Ch. This 
interaction is dependent on the charge density of both TPP and Ch [107, 108]. 
Complexation between oppositely charged species results in precipitation of Ch in the 
form of particles, approximately spherical [49]. Genipin, in turn, is a naturally occurring 
crosslinking agent, commonly used for biomedical applications, given its ability to form 
stable and biocompatible crosslinked products. Genipin reacts with compounds containing 
primary amine groups to form covalently crosslinked networks that are significantly less 
cytotoxic than those crosslinked by glutaraldehyde (a commonly used synthetic 
crosslinking inductor). In the case of Ch, genipin reacts with the free primary amines 
present in the glucosamine units, conferring stability to the microparticles, if crosslinked 
in the optimal proportion [52, 109, 110]. Production of these three-dimensional polymeric 
structures using the referred methods provides controlled size of the particles by variation 
of the compressed air pressure or spray-nozzle diameter.  
 
Figure 8. Chitosan microparticles: Preparation methods. Adapted from Sinha, V. R., et al. [102] 
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Given the purpose of this investigation, Gonçalves et al. [53] have produced 170µm 
microparticles (DA of 15%) using TPP and genipin for ionic and covalent crosslinking, 
respectively. Authors have demonstrated that these particles, although unspecifically, are 
able to bind different strains of H. pylori (namely, J99, 17875/Leb, 17875babA1A2 and 
097UK), decreasing H. pylori adhesion to MKN45 gastric cells and revealing no cytotoxicity 
(in vitro studies) [53]. Moreover, two preliminary in vivo studies using C57BL/6 mice, 
revealed that these Ch Mics were able to reduce the infection with SS1 H. pylori in 
approximately 63% (unpublished data), despite no significant differences were found due 
to variability of infection, suggesting, however, the potential utility of these particles. 
As an effort to improve the removal of H. pylori from the stomach, Ch microparticles 
can be additionally decorated with GlyRs (namely, Leb glycans) on its surface, as already 
demonstrated by Gonçalves et al. (ex vivo studies using sections of the gastric mucosa) 
[10]. To immobilize GlyRs onto microparticles’ surface, authors have reported the use of 
azide-alkyne coupling ("click chemistry") (Figure 9), which maintained their morphology, 
size and stability in simulated gastric fluid. The application of this strategy involved the 
use of primary alcohol groups of Ch, alternatively to primary amines, since these latter 
contribute to the maintenance of chitosan’s mucoadhesiveness [111].  
 
Figure 9. Schematic representation of GlyR immobilization on Ch microspheres. (A) Chitosan, (B) 
Protection of chitosan reactive primary amine groups with phthalic anhydride , (C) Chitosan O-
alkynylation, (D) Immobilization of N3-GlyR using the azide-alkyne “click” coupling, (E) Deprotection 
of chitosan primary amine groups to produce the target GlyR-decorated chitosan microspheres. 
Adapted from Gonçalves et al. [111]. 
 
 Recently, our group has also focused on the reduction of Ch Mics’ size and increase of 
charge, with diameters close to 30µm, using Ch with a DA of 6%, to explore the idea that 
smaller microparticles can penetrate to more internal regions of the gastric foveolae 
(gastric invaginations), where H. pylori is also present and, thus, improve the removal of 
this bacteria. Furthermore, by producing Ch Mics with a lower DA, increases the number of 
amines, which become protonated in the acid gastric pH and can, possibly, enhance the 
binding of H. pylori by electrostatic interactions.  
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Chapter 2 
Motivation and Goals 
2.1. Motivation 
Helicobacter pylori (H. pylori) is among the most common human infections 
worldwide: it colonizes over 50% of the world’s population [25] and 80% to 90% of the 
Portuguese [112]. Although disease is not developed in most infected people, it is a major 
risk factor responsible for the prevalence of various gastrointestinal diseases that range 
from gastritis, to peptic ulcer disease and gastric cancer, among other problems [14, 15]. 
Therefore, the eradication of H. pylori infection becomes crucial for the management of 
these health problems [44, 45]. 
The reduced efficacy of the available treatments to fight H. pylori infection is a 
consequence of the growing resistance of the bacteria to these substances [44, 49], thus, 
it is imperative to develop new studies to fight this infection, using different approaches.  
Recently, the use of chitosan microparticles (Ch Mics) has been given a different 
perspective. A strategy has been described to bind H. pylori, impairing its adhesion to host 
cells and, ultimately, eliminating it from the stomach [53]. The use of these structures as 
binding systems may include chemical modification of microparticles with urease, flagella, 
adhesins and other components as targeting compounds, which may enhance their 
properties and improve their efficacy [49]. In particular, our group has demonstrated the 
possibility of decorating Ch Mics with glycan receptors (GlyRs), namely, Lewis b (Leb), on 
its surface to increase the removal of H. pylori from the stomach [10], taking advantage of 
the specific interactions between Leb receptors and BabA adhesins present in bacteria [10, 
54]. However, despite the potential utility of the proposed treatment, this lacks proper in 
vivo validation and, therefore, it becomes imperative to establish an in vivo model of H. 
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pylori infection for the consequent study of the efficacy of these particles. In parallel, 
cytotoxicity of Ch Mics without surface modifications also needs to be assessed in vitro 
before moving to in vivo tests, where their capacity to adhere and remove H. pylori from 
the stomach should be evaluated.  
Regarding the importance and pertinence of this subject, this new approach reveals 
great interest in the field of biomedical engineering and can, potentially, correspond to an 
innovative solution if further explored. 
2.2. Objectives 
Motivated by the urge of a new treatment for H. pylori infection, the development of 
this investigation was driven by two main goals. Most importantly, this study was intended 
to determine the experimental parameters to establish an H. pylori infection model, using 
an animal model that expresses Leb blood group antigens (as it is the case of C57BL/6 
mice) and a BabA positive bacteria strain of H. pylori.  
 In parallel, the study of chitosan microparticles as a treatment of H. pylori infection 
was developed, assessing their toxicity (in vitro) and evaluating (in vivo) their capacity to 
eradicate these bacteria from the stomach, by oral administration of the particles and 
removal trough the gastrointestinal tract. 
A detailed explanation of the objectives of this study is described below.  
 
A. Establishment of a BabA+ H. pylori infection model 
BabA expression in different H. pylori strains  
The main focus of this study was to find a strategy to establish H. pylori infection in 
C57BL/6 mice (known to express Leb receptors), using a BabA positive strain.  
Therefore, and once H. pylori culture conditions were defined (comparing its motility 
in solid and liquid media), TN2GF4, B128 and SS1 strains were tested for the presence of 
BabA using the Western Blot technique, as an attempt to confirm the expression of this 
adhesin. Again, bacteria were cultured in liquid and solid media to understand if these 
conditions would alter the expression profile of BabA. Extracts from different passages 
were also tested to guarantee that BabA’s expression was not affected overtime. 
H. pylori infection in C57BL/6 mice 
Upon confirmation of BabA expression in B128 and TN2GF4 strains, in vivo 
experiments to infect C57BL/6 mice with H. pylori were carried out, with variation of 
some parameters (namely, administration vehicle, number and volume of inoculum and 
time to develop infection), as an attempt to optimize the development of infection and, 
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thus, to establish an adequate model that could be used in the future to validate the 
efficiency of Leb-coated chitosan microparticles. 
B. Treatment of H. pylori infection using Ch Mics 
Cytotoxicity of Chitosan Microparticles 
Focusing now on the treatment of H. pylori infection, this study suggests the 
employment of Ch Mics (previously characterized by scanning electron microscopy) as a 
binding system for the capture and removal of this bacterium from the stomach. 
Therefore, primarily, the potential cytotoxicity of different amounts of Ch Mics was 
evaluated in vitro, using MKN45 cells, a human gastric carcinoma-derived cell line. 
In vivo mouse model – Eradication of H. pylori infection 
Once tested the cytotoxicity of Ch Mics in vitro, these particles were administered to 
H. pylori infected C57BL/6 mice, in the adequate concentration, to evaluate its efficiency 
in the treatment of H. pylori infection. The bacteria strain chosen to infect the animals 
was the mouse-adapted SS1, as it is an already well-established model, guaranteeing 
development of infection and allowing the study of the suggested treatment. 
 Results obtained in this study can be an important guide to further research in this 
area and will enable in vivo evaluation of Leb-decorated microparticles to target and bind 
specifically H. pylori. This may be transposed to human clinical trials and constitute, 
eventually, a new solution to eradicate the most successful pathogen from the human 
stomach.
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Chapter 3 
Methodology 
 This chapter describes the methodology applied to develop the proposed study. 
It is important to mention that, since this work involved in vivo procedures with mice 
handling, an introductory course in Laboratory Animal Science was attended. The course 
included lectures on rodents, rabbits and fish specific contents, and also practical sessions 
to learn basic procedures, from rodents (mice and rats) handling, to administration of 
substances (using different routes) and euthanasia techniques. In addition, this also 
included a tutorial training at the animal facility to deepen the previously acquired 
knowledge. The course was validated with an appropriate certification at IBMC Training 
Center (FELASA, Category B). 
3.1. H. pylori culture 
Preparation of blood agar plates 
The development of this study included the preparation of agar plates to grow H. 
pylori in vitro. With this purpose, Blood Agar base 2 (approximately 44.4 mg/mL; OXOID, 
Hampshire, UK) was weighed and added to ultrapure water (90% v/v of the desired volume 
of medium). After autoclaving (20min, 115℃), defibrinated horse blood was added (10% 
v/v final, Probiológica, Lisbon, Portugal), together with antibiotics (0.2% v/v final; 
conserved at 4℃ and protected from light). This antibiotic cocktail was prepared with 
polymixine B (0.115 mg/mL; Sigma-Aldrich, Missouri, USA), vancomycin (6.25 mg/mL; 
Sigma-Aldrich), amphotericine B (1.25 mg/mL; Sigma-Aldrich), triméthroprime (3.125 
mg/mL; Sigma-Aldrich) and DMSO (2.5% v/v, Sigma-Aldrich), for the desired volume of 
ultrapure water. About 18-20mL of medium were added to each plate and, after agar 
solidification, these were kept at 4℃ until use.  
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Preparation of BBL 
Brucella broth (BBL) was used in this study as a vehicle for the administration H. 
pylori to mice and also to grow these bacteria in liquid media. With this purpose, 
28mg/mL of brucella broth base (Sigma-Aldrich) were dissolved in ultrapure water, 
autoclaved for 15min, at 121℃, and stored at 4℃. 
Preparation of Peptone water 
The preparation of peptone water consisted in weighing peptone (20 mg/mL, Sigma-
Aldrich) and sodium chloride (5 mg/mL, VWR Chemicals, Radnor, Pennsylvania) to the 
desired volume of ultrapure water. The pH was, then, adjusted to 7.4 and the solution was 
autoclaved (20min, 115℃). 
 
H. pylori strains 
Three H. pylori strains were investigated in this study, namely, SS1, B128 and 
TN2GF4. The first two were obtained from the Unité de Pathogenése de Helicobacter, 
Institut Pasteur (France) and TN2GF4 strain was obtained from the Department of Medical 
Biochemistry and Biophysics, Umea University  (Sweden). 
Growth and collection of H. pylori  
H. pylori aliquots of the different strains cultured (SS1, B128 and TN2GF4) (frozen at -
80℃) were grown (in spots of 20µL each) in blood agar plates, for 32h-48h (37℃, 
microaerophilic conditions). After this time, bacteria were spread and left to grow for 
another 32h-48h in the same conditions. These timepoints established to grow H. pylori 
(32h-48h in each passage) correspond to the exponential growth phase of bacteria, as 
suggested by Parreira, et al. [113]. Bacteria were, then, collected in the adequate 
administration vehicle (peptone water or BBL, depending on the experiment) and 
centrifuged at 3660, for 5min. The supernatant was discarded and the pellet was 
ressuspended in this same vehicle. A sample (diluted 1:100) was used to read the optical 
density at 600nm (OD600) in a spectrophotometer to obtain the concentration of H. pylori. 
3.2 Evaluation of H. pylori motility:  liquid and solid media  
To compare the motility of different H. pylori strains in liquid and solid media (blood 
agar plates and BBL, respectively), SS1 and B128 strains were grown according to the 
methodology described in section 3.1.. Similarly, bacteria grown in the same conditions 
were passaged to liquid media (20 ml of Brucella Broth with 10% heat-inactivated FBS), 
after spotting and spreading growth. Bacteria in liquid media were collected and, after 
centrifuging the suspension (3660, for 5min), the pellet was ressuspended in BBL.
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H. pylori grown in liquid and solid media were analyzed under the optical microscope 
to assess their motility. For that, 10µL of bacterial suspension from each condition were 
placed between two glass coverslips (24x50mm coverslip topped by a 18x18mm 
coversplip).   
3.A. Establishment of a BabA+ H. pylori infection model 
3.A.1 BabA expression in different H. pylori strains  
Collection of the different passages 
H. pylori was grown under the conditions described in section 3.1. Bacteria at passage 
21 were collected after 32h with 1mL PBS. The sample was centrifuged at 5856 rpm, for 
5min. Once this time was over, the supernatant was discarded and lysing buffer, freshly 
prepared, was added. This consisted of 1mL of RIPA 4℃ (50 mL 1M Tris-Cl 7.4 (50mM); 37.5 
mL 4M NaCl (150mM); 4 mL 0.5M EDTA (2mM); 10 mL NP-40 1%; 10 mL 10% SDS (0.1%)), 
10µL of PMSF 100mM (Sigma-Aldrich), 10µL of sodium orthovanadate 100mM (Sigma-
Aldrich) and 40µL of Complete 25% (protease inhibitor cocktail, Roche, Basel, 
Switzerland). The collected bacteria were incubated in this buffer for 15min in ice and, 
then, centrifuged at 3000rpm, for 5min (4℃). Finally, the supernatant, containing the 
protein extract, was stored at -20℃ until use.  
Bacteria grown in the same conditions (section 3.1.) were re-spread onto new blood 
agar plates or cultured in liquid media (20 ml of Brucella Broth with 10% heat-inactivated 
FBS). Both cultures (passage 3, solid media and passage 3, liquid media) were left to grow 
for another 32h and collected after this period, following the methodology already 
explained for protein extraction. 
Protein Quantification 
To quantify the amount of protein present in the samples collected, a BSA calibration 
curve was constructed. With that purpose, eight different concentrations of BSA were 
prepared: 2000µg/mL, 1500µg/mL, 1000µg/mL, 750µg/mL, 500µg/mL, 250µg/mL, 
125µg/mL, 50µg/mL. 5µL of each solution were plated in a 96-well plate in triplicates, 
along with a blank (ultrapure water; also in triplicates). The calibration curve obtained 
allowed the quantification of total protein present in the samples. 
The protein extracts of passage 2 and passage 3 (solid and liquid) of SS1, B128 and 
TN2GF4 H. pylori strains were diluted 1:5 and 1:25 and plated in the 96-well plate (5µL 
                                                 
1 For H. pylori culture, passage 1 was considered the spot phase. Passage 2 corresponds to the first 
spread after bacteria were grown for 32h in spots. Passage 3, in turn, corresponds to a re-spread 
onto liquid or solid media. 
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per well, in triplicates). To determine the protein concentration, the Bio-Rad DC Protein 
assay was used. Absorbance was read in a spectrophotometer at 750nm. 
Western Blot 
Once determined the total protein concentration of each sample (Figure B1, Appendix 
B), it was possible to normalize the amount to load the lanes. Solutions of each sample 
were prepared with the same amount of protein (25µg) on a total volume of 25µL. 
Likewise, aliquots from 17875/Leb and 17876 babA1A2 (positive and negative control, 
respectively) were also prepared. For each solution, 6.25µL of sample buffer (Laemmli 4x - 
277.8 mM Tris-HCl pH 6.8; 44.4% (v/v) glycerol; 4.4 % LDS - e Bromophenol Blue 0.02%), 
together with 10% (v/v) 2-mercaptoethanol, were added. Solutions were heated at 100℃ 
for protein denaturation, for 10min, and separated by 10% Tris-Glycine SDS PAGE, for 1h 
(150V). Transference was performed by electrophoresis onto a Nitrocellulose Blotting 
Membrane 0.45µm (GE Healthcare Life Science, Little Chalfont, UK), for 1h30, 60V. Once 
this process was over, the membrane was blocked with 5% skim milk in PBST (containing 
0.05% Tween 20) for 1h. After washing the membrane (3x) with PBST, AK277 antibody 
(primary antibody), diluted 1:10000 in 5% skim milk in PBST, was added (1mL of antibody 
solution per cm3) and incubated for 2h at RT, under continuous agitation (35 rpm). The 
bound antibodies were detected by horseradish peroxidase-conjugated anti-rabbit Ig 
secondary antibody, followed by ECL detection system, from Amersham (TM) ECL (TM) 
Western Blotting Detection Reagents (GE Healthcare). For the development process of the 
films different exposure times were tested (5s, 10s and 30s). 
3.A.2 H. pylori infection in C57BL/6 mice 
H. pylori infection in C57BL/6 mice included three different studies, with alterations 
in the experimental conditions, as an attempt to establish an infection model for a H. 
pylori BabA positive strain. The study protocol and the experimental parameters used in 
each experiment are described in Figure 10. In Experiment I H. pylori culture and mice 
infection were performed with the parameters already established in our lab, accordingly 
to Correia et al. [75]. Experiment II was performed as an attempt to improve the efficacy 
of the infection, with the alteration of some conditions (Figure 10, Experiment II), namely, 
the administration vehicle (changed to BBL), the number (increased to 3 times) and 
volume of inoculations (doubled) and, finally, the time to develop infection was tested for 
3 and 4 weeks. The last experiment (Experiment III) maintained most of the conditions, 
but H. pylori infection was evaluated only at the end of the 4 weeks timepoint for 3 
different H. pylori strains: SS1, B128 and TN2GF4. 
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Experimental parameters Experiment I Experiment II Experiment III 
Animal model C57BL/6 mice C57BL/6 mice C57BL/6 mice 
Age (weeks) 7 7 7 
Number of animals 8 male mice 14 male mice 15 male mice 
H. pylori strain B128 B128 SS1, B128b, TN2GF4 
Bacterial concentration (CFU/mL) 1010 1010 1010 
Vehicle Peptone Water BBL BBL 
Number of inoculations 2x 3x 3x 
Inoculations volume (mL) 0.1 0.2 0.2 
Time to develop infection (weeks) 3 3 and 4 a 4 
Test Groups Name n Name n Name n 
 Hp- 2 Hp- 3w
c 1 Hp- 1 
 Hp+ 6 Hp- 4w
c 1 Hp+SS1 2 
  Hp+ 3w
c 6 Hp+B128 6 
  Hp+ 4w
c 6 Hp+TN2GF4 6 
a 
From the 12 infected animals, 6 were sacrificed 3weeks post infection (along with one control animal) and the remaining were euthanized one week after (i.e. 4 weeks post infection).  
b In this case, B128 bacteria were collected from a subculture of this strain, obtained from H. pylori positive cultures of mice stomach (from experiment II). 
c
 Time to develop infection. 3w - 3 weeks; 4w – 4 weeks.  
n number of animals; BBL Brucella broth; Hp- Non-infected animals; Hp+ Infected animals 
Figure 10. Experimental conditions, along with test groups’ definition, and study protocol for the different experiments developed for the creation of an H. pylori infection model. 
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H. pylori culture 
The culture of H. pylori for infection comprised the steps described in section 3.1. 
After this period, on the infection day, bacteria were collected with peptone water or BBL 
(according to the parameters defined for each experiment) to a falcon and kept in 
suspension in the corresponding vehicle. 
In order to adjust the bacterial concentration to 1x1010 CFU/mL for the inoculation, a 
spectrophotometer was used to measure the optical density (OD), where it was considered 
a correspondence of OD600=1 to 5x108CFU/mL. Apart from preparing the bacterial 
suspension for mice infection, serial dilutions were performed and dilutions of 105, 106, 107 
and 108 were spotted (10µL/drop) in blood agar plates for CFU counting (4-6 days after) to 
confirm its concentration. The number of CFU/mL present was calculated based on 
equation 1, 
 
𝐶𝐹𝑈 𝑚𝐿 =
𝐶𝐹𝑈×𝐷𝐹
𝑉𝑑𝑟𝑜𝑝
⁄                                                                                              (1), 
 
where CFU corresponds to the number of colony forming units found in the defined volume 
of the spot (Vdrop) and DF is the dilution factor.  
Infection of C57BL/6 mice with H. pylori 
Infection with H. pylori was performed in C57BL/6 mice (7-8 weeks old, specific-
pathogen-free), from Charles River’s company (Massachussetts, USA). During their stay at 
the animal facility, mice were housed, inside ventilated cages, in an ABSL2 room, with a 
12h light/12h dark cycle. Animals were fed with commercial pellet diets and water ad 
libitum and fasted 24h before inoculation (being transferred to clean cages without corn 
cob or food, but with proper enrichment material to guarantee animals’ welfare). Water 
was removed 3h before administration of the bacterial suspension and food/water access 
was re-established 1h to 2h after infection. 
The bacterial suspension (1x1010 CFU/mL) was administered to the animals by oral 
gavage (B.Braun 20G cannula 1.1x32mm, Hesse, Germany), with the correspondent 
number of inoculations of each experiment (with 2 or 3 days interval). Additionally, 
control mice were given the same amount of peptone water or BBL (correspondent to the 
vehicle used to administer bacteria in test groups). 
Animals’ sacrifice 
The animals’ physical appearance was observed twice a week and their weight 
variations were inspected weekly, until sacrifice. Mice (previously fasted for 24h) were 
euthanized by cervical dislocation, with previous anaesthesia (50-75 mg/kg Ketamine and 
0.5-1 mg/kg Medetomidine) through intraperitoneal injection (B. Braun 20G cannula 
0.45x12mm).  
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The blood of anaesthetized animals was collected by cardiac puncture into gel-cot 
activator tubes, which were centrifuged (3500 rpm, 2min) and each supernatant was 
added to an eppendorf and frozen at -20℃.  
After sacrifice, mice stomachs were rinsed in NaCl (to remove food) and cut 
accordingly to the scheme presented in Figure 11. This organ divided into 4 parts (each 
half of the stomach was divided into parts A and B). One portion was collected for 
cryopreservation (cryo vials were placed in a container with liquid nitrogen and then 
stored at -80℃), another for histological analysis and the remaining half (parts A and B) 
were cultured in blood agar plates for CFU’s counting.  
 
Figure 11. Schematic representation of the collection of mice stomach segments 
for analysis (histological analysis, cryopreservation and colonization). Adapted from 
Roberts, A. B. . 
 
Two portions (from different lobes) of mice liver were also collected for 
cryopreservation and histological analysis.  
Histological analysis  
To prepare the samples for histological analysis, each portion of the stomach and liver 
was placed in a cassette and immersed in 10% formalin (Atom Scientific, Manchester, UK) 
for 24h. Particularly, to guarantee that gastric sections were well stretched, these were 
placed between two sponges in the cassettes.  
After this period, cassettes were inserted in a tissue processor, where tissues were 
immersed in solutions of: 70% ethanol, 80% ethanol, 90% ethanol, 2x in 100% ethanol, 3x in 
Clear Rite for 1h each and in 2x Paraffin for 1h and 20 min each). Tissues were, finally, 
embedded in paraffin wax for later analysis of histological sections.  
To analyze the morphology of stomach and liver, 3µm tissue sections from all animals 
were obtained using the microtome. For histological analysis sections were stained with 
Hematoxylin and Eosin (H&E). For that, samples were deparaffinated with xylene (10min 
in xylene and another 5min in a new solution of xylene) and subsequently hydrated with 
ethanol (5min in 100% ethanol, 5min in 96% ethanol, 5min in 70% ethanol) and, then, with 
running water (5min). Samples were stained with Hematoxylin for 2min and, again, rinsed 
B 
A 
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with running water. After being placed in ethanol solutions (2min in 70% ethanol and 2min 
in 96% ethanol), samples were stained with Alcoholic Eosin and, then, dehydrated with 
ethanol (quick passages in 100% ethanol). The last process was the diaphanization with 
xylene (10min in xylene and another 10min in a new solution of xylene). 
Regarding Experiment III (described in section 3.A.1.), modified Giemsa staining was 
also performed to analyze tissue sections, as an attempt to find bacteria in animals’ 
stomach. With this purpose, similarly, samples were deparaffinated with xylene (5min in 
xylene and another 5min in a new solution of xylene) and hydrated in ethanol (quick 
passages in 70% ethanol, 95% ethanol and 100% ethanol), followed by a wash in running 
water (5min). Samples were, then, stained with 2% Giemsa solution for 30min. At the end 
of this period, tissue sections were washed, once again, in running water (5min), passaged 
in ethanol (100% ethanol) and diaphanized with xylene (quick passages). 
After both stainings, samples were mounted with entellan, between each slide 
(76X26mm) and the coverslip (18x18mm), and analyzed under the optical microscope. 
 
Colonization - Colony-forming Assay 
H. pylori infection levels with mice stomach tissue were quantified by colony-forming 
assay. The culture of stomach sections involved the use of blood agar plates, prepared as 
previously described in section 3.1., but supplemented with 50mg/ml Bacitracin (Sigma-
Aldrich) and 20mg/ml Nalidixic Acid (Sigma-Aldrich). Each stomach portion (Parts A and B) 
was collected to an eppendorf with 400L of peptone water, weighed and smashed with a 
tissue homogeneizer using sterile pistons. Dilutions of 101, 102 and 103 were, then, made 
and spread with the correspondent non-diluted solution (10L of each solution) for CFU’s 
counting. After 7-15 days culture as above, colonies were counted, and the number of 
colony forming units per mice stomach and per g were calculated, according to equations 
2 and 3, respectively. 
 
𝐶𝐹𝑈 𝑚𝑖𝑐𝑒 𝑠𝑡𝑜𝑚𝑎𝑐ℎ = (𝐶𝐹𝑈 𝑚𝐿𝑃𝑎𝑟𝑡 𝐴 + ⁄⁄ 𝐶𝐹𝑈 𝑚𝐿𝑃𝑎𝑟𝑡 𝐵)  × 𝑉𝑠𝑜𝑙 × 2⁄                                     (2) 
 
𝐶𝐹𝑈 𝑔 =  
𝐶𝐹𝑈 𝑚𝐿 𝑃𝑎𝑟𝑡 𝐴×𝑉𝑠𝑜𝑙⁄
𝑚𝑠𝑡𝑜𝑚𝑎𝑐ℎ 𝑃𝑎𝑟𝑡 𝐴
+ 
𝐶𝐹𝑈 𝑚𝐿 𝑃𝑎𝑟𝑡 𝐵×𝑉𝑠𝑜𝑙⁄
𝑚𝑠𝑡𝑜𝑚𝑎𝑐ℎ 𝑃𝑎𝑟𝑡 𝐵
 ⁄                                                                  (3) 
 
where CFU/mL can be calculated by equation 1, mstomach is the weight of the gastric 
portion and Vsol is the volume in which each part was ressuspended (400µL). 
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Statistical Analysis 
 To analyze weight variations between the different groups independent samples t-
test was applied. Whenever possible, results from CFUs countings were also compared to 
look for significant differences, using, once again, the independent samples t-test. Results 
were considered significant for p < α (considering α = 0.05).  
3.B. Treatment of H. pylori  infection using Ch Mics 
3.B.1 Chitosan Microparticles  
Chitosan microparticles’ production 
The Ch Mics used in this study have been previously produced in the lab by ionotropic 
gelation into a sodium tripolyphosphate solution, using an aerodynamically assisted 
spraying system. These microparticles were prepared with chitosan with a DA of 6% and 
were crosslinked with 10mM genipin for 45min to prevent dissolution in gastric acidic pH. 
Microparticles were, then lyophilized at –80℃ and stored at 4℃ in ethanol, until use. 
Chitosan microparticles morphology - SEM analysis 
For morphology analysis of Ch Mics using SEM, a sample of lyophilized particles was 
placed on the top of a carbon tape, attached to a sample holder. Ch Mics were analyzed 
using a TM3030(Plus) microscope from Hitachi (Tokyo, Japan). 
3.B.2 Cytotoxicity of Chitosan Microparticles 
Gastric cell line MKN45 culture 
Chitosan microparticles’ cytotoxicity was evaluated in vitro, using the gastric 
carcinoma cell line MKN45. MKN45 gastric cell line, from passage 3, was maintained in 
culture in RPMI 1640 with glutamax and HEPES (Gibco, Life Technologies, California, USA), 
supplemented with 10% heat-inactivated (30min, 56℃) fetal bovine serum and 1% 
penicillin/streptomycin (RPMIc), at 37℃, in a humidified 5% CO2 atmosphere. Culture 
medium was exchanged every 2 days. After expanding the cells in 75cm3 T-flasks these 
were seeded in 24-well plates, with 1mL of cell suspension per plate (at a density of 
5x104cells/mL), under the conditions above mentioned. 
Direct contact assay 
The cytotoxicity of Ch Mics was evaluated by direct contact assay, according to ISO 
international standard 10993-5 [114]. With this in mind, increasing concentrations of Ch 
Mics in RPMIc were prepared to obtain a final concentration in the wells of 1000 Mics/well, 
10 000 Mics/well, 50 000 Mics/well and 100 000 Mics/well. For that, Ch Mics from the 
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stock solution (suspended in ethanol) were centrifuged (5000 rpm, 8min), the ethanol was 
discarded and microparticles were re-suspended in RPMIc, followed by another 
centrifugation (5000 rpm, 8min), and adjusted to the different concentrations. 
Ch Mics were added to the wells with adherent cells (6 replicates per concentration). 
Cells with TCPS microspheres (~270µm in diameter, 75mg/mL) were used as positive 
control of cell metabolic activity to guarantee that cells were not affected if completely 
covered by particles (this guarantees that any change in metabolic activity is caused by 
direct contact with Ch Mics and not because cells are prevented from their normal 
atmosphere) and cells with 10% hydrogen peroxide in RPMIc were used as positive control. 
Cells in RPMIc, RPMIc alone, Ch Mics in RPMIc and TCPS Mics in RPMIc also served as a 
control to determine cells metabolic activity when cultured alone and to guarantee that 
culture media or culture media with Ch Mics would not influence the results from the 
metabolic activity. 
Metabolic activity - Resazurin Assay 
Metabolic activity of MKN45 cells was measured using the resazurin assay, to evaluate 
the cytotoxicity of Ch Mics. With this in mind, 20% resazurin in RPMIc was added to the 
wells and incubated for 4h. Once this incubation period was over, 200µL of supernatant 
were added to a 96-well black plate to measure its fluorescence (𝜆𝑒𝑥 = 530nm and 𝜆𝑒𝑚 = 
590nm), using a microplate fluorometer (Spectra Max GeminiXS, Molecular Devices). Blanks 
for fluorescence emission subtraction were performed with RPMIc, Ch Mics in RPMIc or 
TCPS microspheres in RPMIc. Cell viability was determined based on the percentage of 
metabolic activity of MKN45 cells. 
Immunocytochemistry 
After fixation of cells with 4% PFA (15min), cells were permeabilized with 0.1% Triton 
X-10 for 5min, at 4℃. Wells were, then, rinsed with PBS and phalloidin (Alexa Fluor 488; 
excitation/emission: 499/520 nm), diluted 1:100 in PBS, was added (30 min, protected 
from light). Afterwards, wells were rinsed with PBS to add DAPI 3µg/mL (DAPI; 
excitation/emission: 359/457 nm) (15min protected from light). Finally, cells were 
analyzed under inverted fluorescence microscope. 
Statistical Analysis 
Variations in cellular metabolic activity for the different conditions were analyzed 
using one-way ANOVA. Results were considered significant for p < α (considering α = 0.05).  
3.B.3 In  vivo mouse model - Eradication of H. pylori 
infection 
Infection of C57BL/6 mice with H. pylori 
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Infection with H. pylori was performed in 20 C57BL/6 mice (7-8 weeks old, specific-
pathogen-free), in accordance with the parameters described in Tables IX and X. 
 
Table IX. Experimental parameters for H. pylori infection with SS1 strain. 
Animal model C57BL/6 mice 
Age (weeks) 7 
Number of animals 20 male mice 
Bacteria strain SS1 
Bacterial concentration (CFU/mL) 1010 
Vehicle Peptone water 
Number of inoculations 3x 
Inoculations volume (mL) 0.1mL 
Time to establish infection (weeks) 3 
 
Table X. Test groups in H. pylori 
infection experiment with SS1 strain. 
 
 
 
 
 
 
 
H. pylori culture  
SS1 H. pylori strain was grown in accordance with the methodology described in 
section 3.1 and the preparation of bacteria to infect the animals followed the steps 
presented in section 3.A.1..  
Treatment of H. pylori infection using Ch Mics 
Three weeks after infection, the treatment plan was applied to the animals, during a 
period of 14 days. This involved the daily administration (1 dose/day) of 10 000 Mics in 
100µL of phosphate-citrate buffer pH6, by oral gavage (B. Braun 20G cannula 1.1x32mm). 
A summary of the experimental parameters used in this treatment is presented in Table XI. 
In addition, a study protocol of inoculation, infection and treatment processes is described 
in  
Figure 12. 
 
Table XI. Experimental parameters for Ch Mics treatment – in 
vivo mouse model. 
Treatment duration (days) 14 
Name n 
Hp-Mic- 2 
Hp-Mic+ 2 
Hp+Mic- 8 
Hp+Mic+ 8 
n number of animals;  Hp- Non-
infected animals; Hp+ infected 
animals; Mic- Non-treated 
animals; Mic+ Treated animals. 
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Number of doses 14 (1 dose/day) 
Dosage (Mics/mL) 1x105 
Volume (mL) 0.1 
Vehicle phosphate-citrate buffer pH6 
 
 
Figure 12. Study protocol for SS1 H. pylori infection and treatment (with Ch Mics) 
of C57BL/6 mice. 
 
From the four control animals (not infected with H. pylori), two were given 
phosphate-citrate buffer alone, whereas the remaining were given Mics. The sixteen 
infected animals were, in turn, divided into two groups of eight animals each: one 
received phosphate-citrate buffer and Mics were administered to the other group.  
Animals’ sacrifice 
Animals were sacrificed the day after the end of the treatment plan, accordingly to 
the procedure presented in section 3.A.2.. 
Statistical Analysis 
To test the null hypothesis between the groups (animals’ infected, but without Mics 
treatment, and animals infected and treated), Kruskal-Wallis non-parametric test was 
applied. Results were considered significant for p < α (considering α = 0.05).  
 
Week  0                 1                  2                 3                 4                  5                         
             Day   0    1    2    3     4    5    6    7 
 
H. pylori inoculation 
Infection development 
Sacrifice 
Ch Mics Treatment 
Daily administration 
9h: Water removal 
11h: Administration of Ch  Mics 
16h: Re-establishment of food/water access 
Mics 
 22h (of the previous day): Fasting 
Mics 
             1    2    3     4    5    6    7   8    9   10   11  12  13   14 
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Chapter 4 
Results and Discussion 
In this chapter the results obtained from the methodology applied are presented and 
evaluated, as an attempt to give an answer to the proposed goals.  
4.A. Establishment of a BabA+ H. pylori infection model 
First of all, to evaluate and compare the motility of different H. pylori strains (SS1 
and B128), bacteria were grown in solid and liquid media (blood agar plates and BBL, 
respectively), since these are among the most common culture media reported (as 
described in section 1.4.1.). Bacteria were visualized by optical microscopy (bright field), 
right after collecting them from culture. Comparing solid with liquid media, both strains 
were found to be motile, and mainly in rod morphology, with no apparent differences 
observed between them. For this reason the use of blood agar plates (solid media) was 
adopted in the subsequent experiments to grow H. pylori, since it was already a common 
practice in the lab.   
4.A.1 BabA expression in different H. pylori strains  
To determine the expression of BabA adhesin in TN2GF4, B128 and SS1 strains, a 
Western Blot was performed. With this purpose, protein from these samples was extracted 
and a calibration curve of BSA was used to determine the protein concentration of each 
sample (described in Appendix B). Based on this curve, it was possible to normalize the 
amount of protein to load in each lane (for electrophoresis). 
The detection of BabA adhesin from bacteria grown in solid and liquid media (blood 
agar plates and BBL, respectively) and from different passages was evaluated, using the 
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AK277 primary antibody. Results obtained (Figure 13) confirmed that B128 and TN2GF4 
strains show a band just above the 75kDa ladder mark. This suggests the expression of 
BabA adhesin, known to have a molecular weight of around 78kDa [31], and is supported 
by the presence of this same band in the positive control strain (17875/Leb), which also 
expresses this protein, in agreement with the previously described [40]. Therefore, this 
confirms the results found in our preliminary work for B128 strain (Appendix A, Figure A1) 
and found in the literature for TN2GF4 strain [96]. Moreover, the culture media and the 
different passages do not seem to affect the expression of BabA adhesin. Nevertheless, in 
lanes correspondent to B128 strain culture in solid media (for passages 2 and 3) a second 
band, less pronounced, can be found. A strategy to find the reason underlying these 
results was not pursued, but an incomplete denaturation of proteins could be hypothesized 
as an explanation.  
Concerning the SS1 strain loaded lanes, results showed a band close to 75kDa ladder 
mark. Further research should be performed on these results but a previous study 
(performed by our group collaborators at IPATIMUP, Glycobiology in Cancer Group) already 
pointed to the absence of BabA in this strain (unpublished work) and, in fact, a weaker 
signal, compared with the remaining samples, is found in this case.  
 
 
 
 
 
4.A.2. H. pylori infection of C57BL/6 mice 
Once defined the conditions to culture H. pylori and upon confirmation of BabA 
adhesin expression in B128 and TN2GF4 strains, the development of infection in C57BL/6 
mice with these strains was assessed. With this in mind, different experiments were 
Figure 13. Western Blot analysis of H. pylori SS1, B128 and TN2GF4 strains, for the different 
passages (P2 Passage 2; P3 Passage 3) and culture media (S - solid; L - liquid). 17875/Leb and 
17875 babA1A2 served, respectively, as positive and negative controls. Amount of protein: 25µg; 
Exposure time: 10s. 
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developed, varying some parameters (described in section 3.A.2.) to establish the 
adequate infection model. 
The first experiment was intended to evaluate the applicability of a well-established 
(also in our lab) animal model for SS1 H. pylori strain, but using the BabA positive H. pylori 
strain B128. In other words, the aim of this study was to determine the effectiveness of 
pre-defined conditions (bacterial concentration, number of inoculations and time to 
establish infection) in the establishment of H. pylori infection (presented in Figure 10, 
section 3.A.2.), using B128 strain, by verifying the presence of this bacterium in the 
stomach of C57BL/6 mice.  
After growing H. pylori in blood agar plates, bacteria were inoculated to mice and 
results revealed a bacterial concentration of 1.03x1010 and 1.53x1010 CFU/mL (for each of 
the 2 inoculations, respectively), which was close to the desired value (1x1010 CFU/mL). 
During the development of infection, to assure animals’ welfare, besides inspecting 
their physical appearance, weight variations were registered weekly for each animal, until 
sacrifice, and results are presented in Figure 14 as an average within each group. 
 
 
Figure 14. H. pylori infection – Experiment I: C57BL/6 mice 
weight variations during the development of infection with B128 
H. pylori strain. Groups: Hp- Non-infected animals; Hp+ 
Infected animals. Values from week 0 correspond to the pre-
infection weighing (the day before the first H. pylori 
inoculation), whereas values from weeks 1, 2 and 3 relate to 
post-infection weighings. No significant differences were found 
between groups for each timepoint (Independent samples t-
test).  
Results obtained revealed no significant differences between control and test groups 
and a progressive weight increase was verified over the course of weeks. To understand if 
animals’ weight was in accordance with their normal growth curve, the technical file of 
C57BL/6 mice (from Charles River, their source place) was analysed and their theoretical 
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weight variation curve is presented in Figure C1 Appendix C. At week 0, animals were 7 
weeks old and their weight was around 20g for both groups, which is in accordance with 
the theoretical value described for males. Animals increased their weight over the weeks 
and, at the end of the 3 weeks timepoint, their weights were close to 25g, which, once 
again, corresponds to a normal value for 10 weeks old male mice. 
Despite presenting the results in terms of average weight per group, mice weight 
evolution was also evaluated individually (data not shown). Each animal increased weight 
over time and all mice maintained good physical appearance throughout the experiment.  
Regarding the development of infection in mice, this was assessed by plating the 
animals’ stomach in blood agar and counting the CFUs present (as explained in section 
3.A.2.). Histological analysis of stomach sections was also performed to look for 
morphological changes that could indicate presence of infection. 
Results of the CFUs found in mice stomachs (Figure 15) confirmed that, as expected, 
non-infected animals were H. pylori negative. However, these also revealed that only 1 
out of the 6 infected animals gave positive results for H. pylori culture, with a 
concentration of 5.3x103 CFU/stomach (7.8x104 CFU/g). This suggests that, possibly, the 
conditions applied, already established for infection with SS1 strain, are not adequate for 
the development of B128 H. pylori infection in mice. In fact, for SS1 H. pylori strain, 
studies reveal the presence of 103-106 CFU/g in C57BL/6 mice, 4 weeks post-infection [68, 
77]. And, although the CFUs found in the animal infected were within this range, only one 
animal was infected.  
 
 
Figure 15. H. pylori infection – Experiment I: Colonization of B128 H. pylori strain in C57BL/6 mice 
(CFU/mice stomach and CFU/g) - Colony forming assay. Groups: Hp- Non-infected animals; Hp+ Infected 
animals. 
Regarding the histological analysis of mice stomach sections it was possible to find in 
all animals a well demarked transition between the non-glandular forestomach and the 
glandular stomach, as identified in Figure 16 (margo plicatus). Further analysis of the 
histological sections was compared with images found in the literature (illustrated in 
Figure D1, Appendix D). 
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Figure 16. Histomorphology of C57BL/6 mice (H&E staining). Group Hp- Animal 1. 
The region marked with an arrow corresponds to margo plicatus. Scalebar: 500µm.  
Analyzing in more detail gastric sections of the different animals (Figure 17), it is 
possible to observe that control mice (Group Hp-) presented no alterations in their gastric 
morphology. In what concerns infected animals (Group Hp+), a large inflammatory 
infiltrate can be found in animal Hp+ 3. However, this mouse was not H. pylori positive in 
the colony forming assay. For this reason, these events might not be associated. Regarding 
the only animal found with CFUs in this experiment (animal Hp+ 6), no significant changes 
in the gastric histomorphology could be denoted, suggesting that bacteria did not trigger 
an inflammatory response from this animal’s immune system, for the period defined to 
develop infection (3 weeks).  
Overall, results suggest that the administration of B128 strain to C57BL/6 mice, with 
the parameters applied in this experiment, were not able to develop infection consistently 
and in a reproducible manner. 
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Since the conditions previously applied were not successful in the establishment of an 
H. pylori infection model, a second experiment was carried out, again using the B128 
strain. Yet, some parameters were altered as described in Figure 10 (section 3.A.2.). The 
number of administrations was increased from two to three times and the volume of 
inoculum was doubled (200µL). The bacterial concentration was maintained, accordingly 
to the values suggested in the literature [56, 64, 79]. In this experiment, BBL was used as 
the administration vehicle, instead of peptone water, since its use is most described on 
the literature (see Tables IV, V and VI). In addition, concerning the time to develop 
infection, besides maintaining the 3 weeks timepoint, a group of animals was sacrificed 
after 4 weeks to understand the influence of this parameter. The timepoints were chosen 
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Figure 17. H. pylori infection – Experiment I: Histological characterization (H&E 
staining) of C57BL/6 mice gastric mucosa infected with H. pylori (B128 strain). Groups: 
Hp- Non-infected animals; Hp+ Infected animals. Column A – proximal portion of 
glandular stomach. Column B –distal portion of glandular stomach. Scalebar: 200µm. 
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in accordance with the periods suggested to develop infection in C57BL/6 mice in other 
published studies (see Table VI). Furthermore, in this particular case, and although the 
defined concentration of bacterial suspension was 1x1010 CFU/mL, the density of the 
inoculum administered to mice was 6x109 CFU/mL, 3.67x109 CFU/mL and 4x109 CFU/mL 
(for the 3 inoculations, respectively), given the lack of bacteria obtained.  
Mice weight variations are presented in Figure 18. Similarly and as expected, mice 
varied their weight from approximately 20g at 7 weeks old and were close to 25g after 3 
and 4 weeks. This suggests that the experimental procedures did not affect the normal 
growth of the animals involved. Individually, animals showed good physical appearance in 
the course of the experiment and gradually increased their weight (data not shown). 
 
 
Figure 18. H. pylori infection – Experiment II: C57BL/6 mice weight variations 
during the development of infection with B128 H. pylori strain. Groups: Hp-3w 
Non-infected animals sacrificed 3 weeks post-infection; Hp-4w Non-infected 
animals sacrificed 3 weeks post-infection; Hp+3w Infected animals sacrificed 3 
weeks post-infection; Hp+4w Infected animals sacrificed 4 weeks post-infection. 
Values from week 0 correspond to the pre-infection weighing (the day before H. 
pylori inoculation), whereas values from weeks 2, 3 and 4 relate to post-infection 
weighings. Week 1 is absent as no weighing was performed at this time-point. No 
significant differences were found between groups for each timepoint (Independent 
samples t-test).  
 
Results from CFU’s countings are presented in Figure 19. Once again plates of control 
mice stomachs were absent from H. pylori colonies. From the infected animals, none of 
the mice sacrificed after 3 weeks (Group Hp+3w) were positive for H. pylori culture and 
only 1 out of 6 animals from the 4 weeks group (Group Hp+4w) was infected, with a 
concentration of 3.2x102 CFU/stomach (5.8 CFU/g).  
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Figure 19. H. pylori infection – Experiment II: Colonization of B128 H. pylori strain in C57BL/6 mice (CFU/mice 
stomach and CFU/g) - Colony forming assay. Groups: Hp-3w Non-infected animals sacrificed 3 weeks post-
infection; Hp-4w Non-infected animals sacrificed 3 weeks post-infection; Hp+3w Infected animals sacrificed 3 
weeks post-infection; Hp+4w Infected animals sacrificed 4 weeks post-infection. 
A recent study from Cook, K. et. al. [79] has proven the ability to infect C57BL/6 
mice, with a colonization density ranging from 0.625x105 CFU/g to 3.88x105 CFU/g, using 
approximately the same bacterial concentration (109 CFU/mL, 108 CFU/mice) as in this 
experiment. The only apparent difference seems to be the use of isosensitest broth (see 
Table VI in section 1.4.1.), instead of BBL as inoculation vehicle and, yet, this revealed a 
much higher efficiency in the development of infection. Likewise, studies from Wang, G. 
et al. [80] and Cullen, T. et al. [81] also showed the ability to infect C57BL/6 mice with 
104 CFU/g and 104 to 105 CFU/stomach, respectively. Therefore, although experimental 
conditions were altered to what is reported to be favourable for the growth of H. pylori 
and for the success of the infection, the low amounts of this bacterium, found in only one 
of the animals infected, and the absence of colonies in animals from the 3 weeks 
timepoint might indicate that the development of infection with B128 strain is highly 
variable. 
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Figure 20. H. pylori infection – Experiment II: Histological characterization (H&E 
staining) of C57BL/6 mice gastric mucosa infected with H. pylori (B128 strain). Groups: 
Hp-3w Non-infected animals sacrificed 3 weeks post-infection; Hp-4w Non-infected 
animals sacrificed 3 weeks post-infection; Hp+3w Infected animals sacrificed 3 weeks 
post-infection; Hp+4w Infected animals sacrificed 4 weeks post-infection. Column A – 
proximal portion of glandular stomach. Column B –distal portion of glandular stomach. 
The region identified with an arrow (Hp+3w 1) corresponds to a portion of mice 
pancreas. Images from animal Hp+3w 2 were not obtained, as well as from the distal 
portion of Hp+3w 6. Scalebar: 200µm. 
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From histological analysis of stomach sections (Figure 20), no apparent differences 
between infected (Hp+3w and Hp+4w) and non-infected animals (Hp-3w and Hp-4w) can 
be observed. In fact, animals do not seem to change their gastric epithelial morphology, 
even in the animal with positive culture of H. pylori (animal Hp+4w 3).  
Taking this into consideration, a new experiment was performed using TN2GF4 H. 
pylori. C57BL/6 mice were, thus, infected with this strain and, simultaneously, two other 
groups of animals were tested for the same conditions, using SS1 and B128 strains to 
compare the efficiency of different strains in the establishment of H. pylori infection. SS1 
was used as the positive control, since it is known its ability to infect C57BL/6 for the 
defined conditions. B128 strain was collected from a subculture of these bacteria found in 
mice stomach after colonization in blood agar plates, from the previous in vivo experiment 
(Experiment II, Group Hp+4w 6). Since these bacteria have proven to infect mice, these 
might be able to develop infection more efficiently. The parameters considered in the 
study are presented in Figure 10. 
The weight variations of the animals, displayed in Figure 21, show a progressive 
increase in mice’s weights for the different groups, with no significant differences 
between them, for each timepoint. Additionally, results are in accordance with the values 
suggested in Figure C1 Appendix C, revealing, once again, that animals’ normal growth 
was not affected. All animals were followed individually, having increased their weight 
progressively and maintaining good physical appearance throughout the experiment. 
 
Figure 21. H. pylori infection – Experiment II: C57BL/6 mice weight variations 
during the development of infection with SS1, B128 and TN2GF4 H. pylori strains. 
Groups: Hp- Non-infected animals; Hp+SS1 Animals infected with SS1 H. pylori 
strain; Hp+B128 Animals infected with B128 H. pylori strain; Hp+TN2GF4 
Animals infected with TN2GF4 H. pylori strain. Values from week 0 correspond to 
the pre-infection weighing (the day before H. pylori inoculation), whereas values 
from weeks 1, 2, 3 and 4 relate to post-infection weighings. No significant 
differences were found between groups for each timepoint (Independent samples 
t-test).  
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Results from CFU’s countings are presented in  
 
Figure 22. As expected, the control animal (Hp-1) was found to be H. pylori negative. 
On the other hand, both animals infected with the mouse-adapted strain SS1 (Hp+SS1) 
revealed the presence of these bacteria, with a concentration of 1.24x106 CFU/stomach 
and 4.44x104 CFU/stomach (corresponding to 2.23x104 CFU/g and 7.68x102 CFU/g, 
respectively), in accordance with results found in the literature 4 weeks post-infection 
[68, 77]. In what concerns animals infected with B128 strain (Hp+B128), 5 out of 6 were H. 
pylori positive, with concentrations ranging from 1.55x104 to 1.01x105 CFU/stomach 
(2.13x102 to 2.36x103 CFU/g). Finally, the TN2GF4 strain (Hp+TN2GF4) did not reveal the 
capacity to infect C57BL/6 animals, with no animal presenting positive results for the 
culture of H. pylori. 
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Figure 22. H. pylori infection – Experiment III: Colonization of SS1, B128 and 
TN2GF4 H. pylori strains in C57BL/6 mice (CFU/mice stomach and CFU/g) - 
Colony forming assay. Groups: Hp- Non-infected animals; Hp+SS1 Animals 
infected with SS1 H. pylori strain; Hp+B128 Animals infected with B128 H. 
pylori strain; Hp+TN2GF4 Animals infected with TN2GF4 H. pylori strain. No 
significant differences were found between groups (Independent samples t-
test). 
The results from histological analysis (presented in Figure 23) revealed some minor 
inflammatory infiltrates in Hp-1 animal, which is reported to be a common feature 
inherent to these animals [58]. The same can be found for animals infected with SS1 strain 
(Hp+SS1), suggesting that, even though these were found positive for the culture of H. 
pylori, an inflammatory response was not triggered by the presence of bacteria. 
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Nevertheless, it is visible the presence of atrophy in the distal portion of their stomachs, 
as opposed to non-infected mice, which might indicate the presence of infection.   
Animals infected with B128 strain (Hp+B128), on the other hand, revealed more 
evidenced inflammatory infiltrates (infiltration of mucosal and submucosal lymphocytes), 
especially in animals Hp+B128 3, Hp+B128 4 and Hp+B128 5 spread throughout the entire 
stomach sections. In addition to this, it is visible in all infected animals that the distal 
portion of the stomach (Figure 23, Column B) has suffered an atrophy in comparison with 
the control animal and with normal gastric architecture (Figure D1, Appendix D), which, 
once again, might indicate that B128 was able to successfully infect C57BL/6 mice, leading 
to inflammatory response. Animals infected with TN2GF4 H. pylori strain, besides 
presenting negative cultures of bacteria, also showed no morphological changes and no 
inflammatory response, revealing, once again, the inability of this strain to infect C57BL/6 
mice. 
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Figure 23. H. pylori infection – Experiment III: Histological characterization (H&E 
staining) of C57BL/6 mice gastric mucosa infected with H. pylori (SS1, B128 and 
TN2GF4 strains). Groups: Hp- Non-infected animals; Hp+SS1 Animals infected with SS1 
H. pylori strain; Hp+B128 Animals infected with B128 H. pylori strain; Hp+TN2GF4 
Animals infected with TN2GF4 H. pylori strain. Column A – proximal portion of 
glandular stomach. Column B – distal portion of glandular stomach. Scalebar: 200µm. 
To further explore the results found in animals infected with B128 H. pylori strain, 
stomach sections were stained with modified Giemsa, as an attempt to find bacteria. A 
representative illustration (Group Hp+B128, animal 4) of the results can be found in Figure 
24, where it is possible to identify H. pylori on the surface of the gastric mucosa, 
confirming that the B128 strain, isolated from an infected animal’s stomach (Experiment 
II, Group Hp+4w, animal 6), was more prone to survive and thrive in mice stomach, being 
able to infect more effectively these animals. In fact, other study from Peek, R. et al. had 
already suggested that serial passages of H. pylori in rodents increases colonization 
efficiency [115], supporting the results found in this study. 
 
H
p
+
T
N
2
G
F
4
 4
 
H
p
+
T
N
2
G
F
4
 5
 
H
p
+
T
N
2
G
F
4
 6
 
A B 
  
4.A. Establishment of a BabA+ H. pylori infection model 
 
61 
 
 
Figure 24. H. pylori infection – Experiment III: Histological characterization (Modified Giemsa staining) of C57BL/6 mice 
gastric mucosa infected with B128 H. pylori strain. Representative illustration of C57BL/6 mice gastric section (Group 
Hp+B128, animal 4). The arrow identifies the presence H. pylori. Scalebar: 50µm.  
  
 To complement the histological analysis, mice liver sections were also stained with 
H&E to look for possible morphological alterations. Results, presented in Figure 25, show 
no apparent differences between infected and non-infected animals. From all liver 
sections, it is possible to find hepatocytes that form hepatic cords, distributed radially 
around central veins, which is described as the normal structure of this organ [1]. It is to 
note, though, that all animals present steatosis, an hepatic fat accumulation, resultant 
from a diet rich in carbohydrate, which animals are subjected to. 
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Figure 25. H. pylori infection – Experiment III: Histological characterization (H&E 
staining) of C57BL/6 mice liver. (A) Non-infected animal (Group Hp-, animal 1); (B) 
Animal infected with SS1 H. pylori strain (Group Hp+SS1, animal 2); (C) Animal 
infected with B128 H. pylori strain (Group Hp+B128, animal 4); (D) Animal infected 
with TN2GF4 H. pylori strain (Group Hp+TN2GF4, animal 10). A, B, C, D – Scalebar: 
200µm; E – Scalebar: 50µm. The arrow highlights a region where it is possible to see 
steatosis.   
4.B. Treatment of H. pylori  infection using Ch Mics 
In parallel with the establishment of H. pylori infection, using a BabA positive strain, 
the potential utility of chitosan microparticles as a treatment for H. pylori infection was 
also explored.  
Therefore, primarily, Ch Mics were analysed morphologically and their cytotoxicity 
was evaluated in vitro, using MKN45, a human gastric carcinoma-derived cell line. Once 
this was achieved, a non-cytotoxic concentration of Ch Mics was administered to infected 
mice to evaluate their efficacy in the removal of H. pylori from C57BL/6 mice stomachs. In
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this study, mice were infected with mouse-adapted SS1 strain, a well-established model 
that guarantees development of infection. It is to note, though, that, since SS1 is not BabA 
positive and as Ch Mics are not decorated with Leb receptors, the binding of H. pylori did 
not rely on adhesin-glycans interactions, binding non-specifically to these bacteria. 
4.B.1 Chitosan Microparticles  
The morphology of Ch Mics was analyzed by SEM (Figure 26). Results reveal that the 
particles have irregular shapes and their diameters are around 40µm. Regarding their 
chemical composition, as expected [10], microparticles are mainly composed by carbon, 
having also oxygen and nitrogen in their structure.  
 
 
Figure 26. SEM images of Ch Mics. (A) Scalebar: 200µm; (B) Scalebar: 50µm; (C) Chemical composition 
and dimensions of Ch Mics. 
4.B.2 Cytotoxicity of Chitosan Microparticles 
In what concerns the cytotoxicity of Ch Mics, different concentrations were tested in 
vitro (1000 Mics/well, 10 000 Mics/well, 50 000 Mics/well and 100 000 Mics/well) by direct 
contact assay (as illustrated in Figure 27), using MKN45 gastric cell line.  
C 
B A 
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Metabolic activity of cells was determined after 4h of incubation with resazurin and 
results are presented in Figure 28. As expected, cells cultured with H2O2 presented a 
vestigial metabolic activity of 1%, which was significantly different from the results of 
cells cultured in the remaining conditions. Moreover, cells cultured with TCPS Mics, 
although significantly different from MKN45 cultured alone, revealed high metabolic rates, 
close to 90%. Analyzing, now, cells’ metabolic activity when in direct contact with Ch 
Mics, these were all significantly different from cells cultured alone, except for a Ch Mics 
concentration of 1000 Mics/well. Between groups, cells cultured with 50 000 Mics/well and 
100 000 Mics/well presented a significant decrease in metabolic activity, compared to 
wells with 1000 Mics and 10 000 Mics. Similarly, cells with 100 000 Mics/well presented 
significantly lower metabolic activity, in comparison with cells with TCPS Mics, suggesting 
that, in some extend, Ch Mics influence the behaviour of cells. In any case, metabolic 
activity of cells was maintained above 70%, which respects the restrictions imposed by ISO 
10993-5 [114] to consider a material non-cytotoxic.  
Cells + 1000 Ch Mics/well Cells + 10 000 Ch Mics/well Cells + 50 000 Ch Mics/well 
Cells + 100 000 Ch Mics/well Cells with TCPS Mics 
C 
D E 
Figure 27. Optical microscopy images of a 24-well plate with increasing concentrations of Ch Mics. 
Scalebar: 1 mm. 
Cells + TCPS Mics 
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Figure 28. Metabolic activity (%) of MKN45 cells in the presence of increasing 
concentrations of Ch Mics. Cells with hydrogen peroxide (H2O2) were used as the 
positive control. Cells with TCPS microspheres served as negative control and 
cells with 10% H2O2 in RPMIc were used as negative control. * Metabolic activity of 
cells with H2O2 was significantly different from all the remaining conditions (p < 
0.05). All conditions were significantly different from cells cultured alone, except 
cells with 1000 Mics/well.  
 
In parallel with this study, our group also evaluated the cytotoxicity of Ch Mics using 
the AGS human gastric adenocarcinoma cell line. For this, results revealed a metabolic 
activity ranging from 92.4% to 99.6%, where the highest values were found for cells 
cultured with 1000 Mics/well and 10 000 Mics/wells.  
Cells in the different conditions were stained by immunohistochemistry and results 
are presented in Figure 29. Results show that, in comparison with cells alone, 
microparticles do not seem to alter the normal conformation and distribution of cells. The 
same can be verified for the cells cultured with TCPS Mics. On the other hand, H2O2 in 
culture with MKN45 killed practically every cell.  
Based on these and the results obtained for MKN45 cell line, 10 000 Ch Mics was the 
value defined to administer these particles to mice. 
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Figure 29. Immunofluorescence images of MKN45 gastric cells after 24h of incubation with increasing concentrations of Ch 
Mics. F-actin citoskeleton of the cells appear in green while their nuclei are coloured in blue. Scalebar: 500µm. 
4.B.3 Treatment of H. pylori infection using Ch Mics – In 
vivo mouse model 
Once tested the cytotoxicity of Ch Mics in vitro, the particles were administered to 
C57BL/6 mice (10 000 Mics/mice) to evaluate its efficiency in the treatment of H. pylori 
infection. Three weeks after bacteria inoculation (the time established to develop 
infection), infected mice were treated with Ch Mics for a period of 14 days. This period 
was defined as the treatment duration for this study since the common approach to treat 
H. pylori infection currently in clinical practice (PPI-based triple therapy) suggests 
treatment regimens of 14 days [116-119]. 
Similarly to the previous studies, animal weight variations were analyzed (Figure 30). 
It is possible to observe that, despite the various oral gavages and handling of animals, 
these maintained their good physical appearance. Besides, at the end of the experiment, 
Cells Cells + 1000 Ch Mics/well Cells + 10 000 Ch Mics/well 
Cells + 50 000 Ch Mics/well Cells +100 000 Ch Mics/well Cells + TCPS Mics 
Cells + H2O2 
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animals had the expected weight for their age (12 weeks old), as it is possible to infer 
from the analysis of Figure C1 Appendix C.  
 
 
Figure 30. Efficacy of treatment against H. pylori infection: C57BL/6 weight 
variations during the development of infection with SS1 H. pylori strain. 
Groups: Hp-Mic- non-infected and non-treated mice; Hp-Mic+ non-infection but 
treated mice; Hp+Mic- infected but non-treated mice; Hp+Mic+ infected and 
treated mice. Values from week 0 correspond to the pre-infection weighing (the 
day before H. pylori inoculation), whereas values from weeks 1, 2 and 3 relate 
to post-infection weighings. * Significant differences (p < 0.05; Kruskal-Wallis 
non-parametric test).  
 
To evaluate the effectiveness of this H. pylori infection treatment, animals’ stomachs 
were plated and grown in blood agar plates for CFU’s counting. Results obtained are 
illustrated in Figure 31. 
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Figure 31. Efficacy of treatment against H. pylori infection. Presence of SS1 strain in 
C57BL/6 mice (CFU/mice stomach). Groups: Hp-Mic- non-infected and non-treated mice; 
Hp-Mic+ non-infection but treated mice; Hp+Mic- infected but non-treated mice; Hp+Mic+ 
infected and treated mice. No significant differences were found between groups.  
 
As it is possible to observe, non-infected animals were not H. pylori culture positive, 
according to the expected. Regarding the development of infection in non-treated mice 
(Hp+Mic-), and in comparison with other published studies, the CFUs found were close to 
the lowest levels reported as, for this mouse strain, several authors indicate that 1 month 
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after infection, animals have a concentration of approximately 103 to 106 CFU/g tissue of 
H. pylori [61, 68, 77, 82]. 
In what concerns the comparison between treated (Hp+Mic+) and non-treated animals 
(Hp+Mic+), no significant differences were found. However, mice treated with Ch Mics 
showed higher number of CFUs per mice (with the exception of one mouse that presented 
no CFU). A possible explanation may be the fact that SS1 H. pylori infection was not 
homogenous, resulting in greater infection rates in some cases, when compared to others. 
This might have hidden possibly significant differences, translating into an unsuccessful 
reduction of infection. Nevertheless, the group has previously tested the use of Ch Mics 
(but with 170µm in diameter) and was able to reduce, although not significantly, the 
infection with SS1 H. pylori in approximately 63% (unpublished data), which might still be 
an indication of the potential of these particles to treat H. pylori infection. 
Images obtained from histological analysis of stomach sections (Figure 32) reveal that, 
similarly to the previous experiments, non-infected animals (Hp-Mic- and Hp-Mic+) have 
normal gastric architecture and, particularly, the administration of Ch Mics to non-
infected animals did not seem to trigger an inflammatory response, which, once again, 
might indicate that these Mics are non-cytotoxic.  
Regarding animals infected and untreated (Hp+Mic-), results showed the presence of 
some inflammatory infiltrates. And, finally, in animals treated with Ch Mics (Hp+Mic+), the 
only animal found with no CFUs (Hp+Mic+ 7) also presented a normal morphology, which 
supports once again the hypothesis of this mice being treated. For the remaining animals 
of this group, a more evidenced inflammatory infiltrate could be found in one of the 
animals with positive CFUs, which might be caused by H. pylori, despite the presence of 
Ch Mics. Furthermore, all infected animals presented atrophy in the distal portion of the 
stomach, which might suggest that these events are correlated.  
In this study, histological sections of mice’s liver were also analysed to look for 
morphological changes caused by the presence of Ch Mics. As it is possible to find in Figure 
33 and comparing with histological sections of liver with morphological changes (Figure D2, 
Appendix D), these Mics do not seem to cause any changes in this organ suggesting, once 
again, no cytotoxicity. 
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Figure 32. Efficacy of treatment against H. pylori infection: Histological 
characterization (H&E staining) of C57BL/6 mice gastric mucosa infected with H. pylori 
(SS1 strain). Groups: Hp-Mic- non-infected and non-treated mice; Hp-Mic+ non-
infection but treated mice; Hp+Mic- infected but non-treated mice; Hp+Mic+ infected 
and treated mice. Column A – proximal portion of glandular stomach. Column B –distal 
portion of glandular stomach. Scalebar: 200µm.  
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Hp-Mic- Hp-Mic+ 
Hp+Mic- Hp+Mic+ 
Figure 33. Efficacy of treatment against H. pylori infection: Histological characterization (H&E 
staining) of C57BL/6 mice liver. Groups: Hp-Mic- non-infected and non-treated mice; Hp-Mic+ non-
infection but treated mice; Hp+Mic- infected but non-treated mice; Hp+Mic+ infected and treated 
mice. Scalebar: 200µm.  
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Chapter 5 
Conclusion 
In the present study, several strategies to establish H. pylori infection with a BabA 
positive strain were explored, as an attempt to enable the study of an innovative 
treatment based on the capacity of Leb-coated Ch Mics to specifically bind these bacteria.  
The establishment of an H. pylori infection model was based on the specific 
interactions between Leb receptors and BabA adhesin. Results revealed that inoculating 
C57BL/6 mice with 1x1010 CFU/mL (0.2mL; 3 inoculations in one week) of B128 BabA 
positive H. pylori strain (isolated from infected mice) in BBL successfully infected 5 out 6 
animals, with 1.55x104 to 1.01x105 CFU/stomach (2.13x102 to 2.36x103 CFU/g). 
Regarding the use of Ch Mics as a potential treatment for H. pylori infection, first, 
their cytotoxicity was evaluated in vitro, when in direct contact with MKN45 gastric cells. 
Cells maintained high rates of metabolic activity and did not alter the morphology of cells. 
These results allowed the determination of an optimal concentration to administer to mice 
(10 000 Ch Mics/mice) to assess their in vivo capacity of treating H. pylori infection. Ch 
Mics did not prove to be able to reduce this infection and, so, further research needs to be 
performed on this topic. 
5.1. Future Perspectives 
Taking into consideration the results found, a new experiment using the same 
conditions described for experiment III is ongoing, to understand its reproducibility and to 
validate the infection model established.  
Regarding future developments, the expression of BabA in B128 strain, isolated from 
an infected animal, should be confirm to guarantee the utility of the infection model. PCR 
  
References 
78 
 
could also be used as another method for the detection and/or quantification of H. pylori 
in infected animals. Finally, to better evaluate the extent of H. pylori infection 
immunohistochemistry of mice gastric sections for the proliferation index marker KI-67 
could be an interesting approach. This monoclonal antibody Ki-67 is directed against a 
nuclear antigen present only in proliferating cells (G1, S, G2 and M phases of the cell 
cycle) and is helpful in the detection of infected and inflamed tissue [120, 121].  
 Considering the study of the cytotoxicity of Ch Mics, non-carcinoma-derived cell lines 
could also be tested, as suggested by Dai, J. et al. [122] 
 In what concerns the treatment of H. pylori infection with Ch Mics, a combination of 
different sized particles, and with different degrees of acetylation, could be tested, 
allowing, eventually, a more efficient removal of H. pylori from the stomach.  
 Additionally, and once both H. pylori infection and the features of Ch Mics are 
optimized, these particles should be decorated with Leb receptors, to target H. pylori 
specifically and more effectively, and be evaluated using the infection model herein 
optimized, using a BabA positive H. pylori strain and Leb-expressing mice. 
 Ideally, these experiments should evolve to human trials to better understand the 
real effectiveness of the proposed treatment, as it is known that, despite the undeniable 
value of using animal models, results obtained from these experiments cannot be fully 
extrapolated to humans. 
 
 
 
 79 
 
References 
1. Seeley, R.R., Stephans, T.D., Tate, P., Anatomy and Physiology. 7th Edition ed. 
2006: McGraw-Hill Higher Education. 
2. Margaret E. S., D.G.M., The Digestive System: Basic Science and Clinical 
conditions. 2010: Elsevier Limited. 
3. American Cancer Society. Nov 2014; 
http://www.cancer.org/cancer/stomachcancer/. 
4. Marieb, E.N. and K. Hoehn, Human anatomy & physiology. 2007: Pearson 
Education. 
5. Agur A. M. R., L.M.J., Grant J. C. B., Grant's Atlas of Anatomy. 10th edition ed. 
1999, London, UK: Lippincott Williams and Wilkins. 
6. Saladin, K., Anatomy & Physiology. 5th edition ed. A Unity of Form and Function. 
2009: McGraw-Hill Companies. 
7. Britannica, E., Human Digestive System: Stomach. 2010. 
8. Lindén, S., et al., Strain-and blood group–dependent binding of< i> Helicobacter 
pylori</i> to human gastric MUC5AC glycoforms. Gastroenterology, 2002. 123(6): 
p. 1923-1930. 
9. Magalhaes, A. and C. Reis, Helicobacter pylori adhesion to gastric epithelial cells 
is mediated by glycan receptors. Brazilian Journal of Medical and Biological 
Research, 2010. 43(7): p. 611-618. 
10. Inês C. Gonçalves, A.M., Ana M S Costa, José R Oliveira, Paula Gomes, Celso A 
Reis, M Cristina L Martins, Bacteria-targeted biomaterials: glycan-coated 
microspheres to bind and remove Helicobacter pylori. Submitted to Acta 
Biomaterialia. 
11. Mollicone, R.B., J.; Lependu, J.; Oriol, R., Pattern of Type-1 (Lea, Leb) and Type-
2 (X, Y, H) Blood Group-Related Antigens in the Human Pyloric and Duodenal 
Mucosae. Lab Invest, 1985. 53(2): p. 219-227. 
12. Wang, X., Helicobacter pylori infection in a mouse model: Development, 
optimization and inhibitory effects of antioxidants. 2001: Lund University. 
13. National Cancer Institute - Stomach Cancer. Nov 2014; 
http://www.cancer.gov/cancertopics/types/stomach. 
  
References 
80 
 
14. Stolte, M. and A. Meining, Helicobacter pylori and gastric cancer. The oncologist, 
1998. 3(2): p. 124-128. 
15. Uemura, N., S. Okamoto, and S. Yamamoto, H. pylori infection and the 
development of gastric cancer. Keio J Med, 2002. 51 Suppl 2: p. 63-8. 
16. Wroblewski, L.E., R.M. Peek, Jr., and K.T. Wilson, Helicobacter pylori and gastric 
cancer: factors that modulate disease risk. Clin Microbiol Rev, 2010. 23(4): p. 713-
39. 
17. Tomb, J.-F., et al., The complete genome sequence of the gastric pathogen 
Helicobacter pylori. Nature, 1997. 388(6642): p. 539-547. 
18. Rama Bansil, J.C., Uncovering the Secrets of Ulcer-causing Bacteria, in Clever 
biochemical strategy enables bacteria to move freely and colonize host. 2009: 
National Science Foundation. 
19. Kusters, J.G., A.H. van Vliet, and E.J. Kuipers, Pathogenesis of Helicobacter pylori 
infection. Clinical microbiology reviews, 2006. 19(3): p. 449-490. 
20. Aspholm, M., et al., SabA Is the H. pylori Hemagglutinin and Is Polymorphic in 
Binding to Sialylated Glycans. PLoS Pathogens, 2006. 2(10): p. e110. 
21. HLT, M., GL, Mendz, SL, Hazell. , Helicobacter pylori: Physiology and Genetics. 
Part II, Bacteriology. 2001, Washington (DC): ASM Press. 
22. Benktander, J., et al., Redefinition of the carbohydrate binding specificity of 
Helicobacter pylori BabA adhesin. J Biol Chem, 2012. 287(38): p. 31712-24. 
23. Azevedo, M., et al., Infection by Helicobacter pylori expressing the BabA adhesin 
is influenced by the secretor phenotype. The Journal of pathology, 2008. 215(3): 
p. 308-316. 
24. Parreira, P., et al., Bioengineered surfaces promote specific protein–glycan 
mediated binding of the gastric pathogen Helicobacter pylori. Acta biomaterialia, 
2013. 9(11): p. 8885-8893. 
25. Dunne, C., B. Dolan, and M. Clyne, Factors that mediate colonization of the 
human stomach by Helicobacter pylori. World J Gastroenterol, 2014. 20(19): p. 
5610-5624. 
26. Rossez, Y., et al., The lacdiNAc-specific adhesin LabA mediates adhesion of 
Helicobacter pylori to human gastric mucosa. J Infect Dis, 2014. 210(8): p. 1286-
95. 
27. Alm, R.A., et al., Genomic-sequence comparison of two unrelated isolates of the 
human gastric pathogen Helicobacter pylori. Nature, 1999. 397(6715): p. 176-180. 
28. Backert, S., M. Clyne, and N. Tegtmeyer, Molecular mechanisms of gastric 
epithelial cell adhesion and injection of CagA by Helicobacter pylori. Cell 
Commun Signal, 2011. 9(1): p. 28. 
 81 
 
29. Saito, N., et al., Coccoid formation as a mechanism of species-preservation in 
Helicobacter pylori: an ultrastructural study. Hokkaido Igaku Zasshi, 2008. 83(5): 
p. 291-5. 
30. Kusters, J.G., et al., Coccoid forms of Helicobacter pylori are the morphologic 
manifestation of cell death. Infect Immun, 1997. 65(9): p. 3672-9. 
31. Wadström, L.A.a.T., Basic bacteriology and culture. Helicobacter pylori: 
Physiology and Genetics, ed. G.M.a.S.H. HLT Mobley. Vol. . 2001, Washington, 
D.C.: ASM press. 
32. Enroth, H., et al., Helicobacter pylori strain types and risk of gastric cancer: a 
case-control study. Cancer Epidemiology Biomarkers & Prevention, 2000. 9(9): p. 
981-985. 
33. Styer, C.M., et al., Expression of the BabA adhesin during experimental infection 
with Helicobacter pylori. Infection and immunity, 2010. 78(4): p. 1593-1600. 
34. Rad, R., et al., The Helicobacter pylori blood group antigen-binding adhesin 
facilitates bacterial colonization and augments a nonspecific immune response. 
The Journal of Immunology, 2002. 168(6): p. 3033-3041. 
35. Sheu, B.-S., et al., Development of Helicobacter pylori Infection Model in BALB/c 
Mice with Domestic cagA-Positive and-Negative Strains in Taiwan. Digestive 
Diseases and Sciences, 1999. 44(5): p. 868-875. 
36. Marie, M.A.M., Relationship between Helicobacter pylori Virulence Genes and 
Clinical Outcomes in Saudi Patients. J Korean Med Sci, 2012. 27(2): p. 190-3. 
37. Yu, J., et al., Relationship between Helicobacter pylori babA2 status with gastric 
epithelial cell turnover and premalignant gastric lesions. Gut, 2002. 51(4): p. 480-
484. 
38. Hennig, E.E., et al., Heterogeneity among Helicobacter pylori Strains in 
Expression of the Outer Membrane Protein BabA. Infection and Immunity, 2004. 
72(6): p. 3429-3435. 
39. Tummuru, M., T. Cover, and M. Blaser, Cloning and expression of a high-
molecular-mass major antigen of Helicobacter pylori: evidence of linkage to 
cytotoxin production. Infection and immunity, 1993. 61(5): p. 1799-1809. 
40. Magalhaes, A., et al., Fut2-null mice display an altered glycosylation profile and 
impaired BabA-mediated Helicobacter pylori adhesion to gastric mucosa. 
Glycobiology, 2009. 19(12): p. 1525-36. 
41. McClain, M., et al., Genome sequence analysis of Helicobacter pylori strains 
associated with gastric ulceration and gastric cancer. BMC Genomics, 2009. 10(1): 
p. 3. 
  
References 
82 
 
42. Bindayna, K.M. and A. Al Mahmeed, vacA genotypes in Helicobacter pylori strains 
isolated from patients with and without duodenal ulcer in Bahrain. Indian Journal 
of Gastroenterology, 2009. 28(5): p. 175-179. 
43. Malfertheiner, P., et al., Management of Helicobacter pylori infection—the 
Maastricht IV/Florence consensus report. Gut, 2012. 61(5): p. 646-664. 
44. Egan, B.J., et al., Treatment of Helicobacter pylori Infection. Helicobacter, 2008. 
13(s1): p. 35-40. 
45. Papastergiou, V., S.D. Georgopoulos, and S. Karatapanis, Treatment of 
Helicobacter pylori infection: Past, present and future. World journal of 
gastrointestinal pathophysiology, 2014. 5(4): p. 392. 
46. Perri, F., et al., Treatment of Helicobacter pylori infection. Helicobacter, 2003. 
8(s1): p. 53-60. 
47. O'Connor, A., J. Gisbert, and C. O’Morain, Treatment of Helicobacter pylori 
infection. Helicobacter, 2009. 14(s1): p. 46-51. 
48. GLOBOCAN, Stomach Cancer: Estimated Incidence, Mortality and Prevalence 
Worldwide in 2012. 2012. 
49. Gonçalves, I.C., et al., The potential utility of chitosan micro/nanoparticles in 
the treatment of gastric infection. Expert review of anti-infective therapy, 2014. 
12(8): p. 981-992. 
50. Salcedo, J.A. and F. Al-Kawas, Treatment of Helicobacter pylori infection. 
Archives of internal medicine, 1998. 158(8): p. 842-851. 
51. Graham, D., et al., Challenge model for Helicobacter pylori infection in human 
volunteers. Gut, 2004. 53(9): p. 1235-1243. 
52. Fernandes, M., et al., Modulation of stability and mucoadhesive properties of 
chitosan microspheres for therapeutic gastric application. International journal of 
pharmaceutics, 2013. 454(1): p. 116-124. 
53. Gonçalves, I.C., et al., Bacterial-binding chitosan microspheres for gastric 
infection treatment and prevention. Acta biomaterialia, 2013. 9(12): p. 9370-
9378. 
54. Parreira, P., Specific binding of the gastric pathogen Helicobacter pylori by 
bioengineered surfaces. 
55. Mitchell, H., et al., Helicobacter pylori: Physiology and genetics. Helicobacter 
pylori: Physiology and genetics, 2001. 
56. Wirth, H.-P., et al., Experimental infection of Mongolian gerbils with wild-type 
and mutant Helicobacter pylori strains. Infection and immunity, 1998. 66(10): p. 
4856-4866. 
57. Ghoshal, N. and H. Bal, Comparative morphology of the stomach of some 
laboratory mammals. Laboratory animals, 1989. 23(1): p. 21-29. 
 83 
 
58. Piper M. Treuting, S.M.D., Comparative Anatomy and Histology: A Mouse and 
Human Atlas. 1st ed, ed. E. Inc. 2012. 
59. Gad, S.C., Animal Models in Toxicology Second Edition ed, ed. C. Press. 2006. 
60. Fox, J.G., The Mouse in Biomedical Research: Normative biology, husbandry, and 
models. 2007: Elsevier. 
61. Lee, A., et al., A standardized mouse model of Helicobacter pylori infection: 
introducing the Sydney strain. Gastroenterology, 1997. 112(4): p. 1386-97. 
62. Ferrero, R. and J. Fox, In vivo modeling of Helicobacter-associated 
gastrointestinal diseases. 2001. 
63. Walsh, E. and A. Moran, Influence of medium composition on the growth and 
antigen expression of Helicobacter pylori. Journal of applied microbiology, 1997. 
83(1): p. 67-75. 
64. Israel, D.A., et al., Helicobacter pylori strain-specific differences in genetic 
content, identified by microarray, influence host inflammatory responses. J Clin 
Invest, 2001. 107(5): p. 611-20. 
65. Rabelo-Gonçalves, E., N.F. Nishimura, and M.R. Zeitune, Development of a BALB/c 
mouse model of Helicobacter pylori infection with fresh and frozen bacteria. 
Biological research, 2005. 38(1): p. 101-109. 
66. Kim, D., et al., Long‐term evaluation of mice model infected with Helicobacter 
pylori: focus on gastric pathology including gastric cancer. Alimentary 
pharmacology & therapeutics, 2003. 18(s1): p. 14-23. 
67. Konturek, P.C., et al., Mouse model of Helicobacter pylori infection: studies of 
gastric function and ulcer healing. Aliment Pharmacol Ther, 1999. 13(3): p. 333-
46. 
68. Salama, N.R., et al., Vacuolating cytotoxin of Helicobacter pylori plays a role 
during colonization in a mouse model of infection. Infection and immunity, 2001. 
69(2): p. 730-736. 
69. Ding, S.-Z. and P.-Y. Zheng, Helicobacter pylori infection induced gastric cancer; 
advance in gastric stem cell research and the remaining challenges. Gut Pathog, 
2012. 4(1): p. 18. 
70. Watanabe, T., et al., Helicobacter pylori infection induces gastric cancer in 
Mongolian gerbils. Gastroenterology, 1998. 115(3): p. 642-648. 
71. Fagerberg, D., et al., Novel Leb-like Helicobacter pylori-binding glycosphingolipid 
created by the expression of human α-1, 3/4-fucosyltransferase in FVB/N mouse 
stomach. Glycobiology, 2009. 19(2): p. 182-191. 
72. Falk, P.G., et al., Expression of a human alpha-1, 3/4-fucosyltransferase in the 
pit cell lineage of FVB/N mouse stomach results in production of Leb-containing 
glycoconjugates: a potential transgenic mouse model for studying Helicobacter 
  
References 
84 
 
pylori infection. Proceedings of the National Academy of Sciences, 1995. 92(5): p. 
1515-1519. 
73. Guruge, J.L., et al., Epithelial attachment alters the outcome of Helicobacter 
pylori infection. Proceedings of the National Academy of Sciences, 1998. 95(7): p. 
3925-3930. 
74. Pohl, M.A., et al., Host-dependent Lewis (Le) antigen expression in Helicobacter 
pylori cells recovered from Leb-transgenic mice. The Journal of experimental 
medicine, 2009. 206(13): p. 3061-3072. 
75. Correia, M., et al., Docosahexaenoic acid inhibits Helicobacter pylori growth in 
vitro and mice gastric mucosa colonization. PloS one, 2012. 7(4): p. e35072. 
76. Wang, X., et al., RAPD-PCR, histopathological and serological analysis of four 
mouse strains infected with multiple strains of Helicobacter pylori. Microbial 
Ecology in Health and Disease, 1999. 10(3-4): p. 148-154. 
77. Ferrero, R.L., et al., Immune responses of specific-pathogen-free mice to chronic 
Helicobacter pylori (strain SS1) infection. Infection and immunity, 1998. 66(4): p. 
1349-1355. 
78. Lemke, L.B., et al., Concurrent Helicobacter bilis infection in C57BL/6 mice 
attenuates proinflammatory H. pylori-induced gastric pathology. Infection and 
immunity, 2009. 77(5): p. 2147-2158. 
79. Cook, K.W., et al., CCL20/CCR6-mediated migration of regulatory T cells to the 
Helicobacter pylori-infected human gastric mucosa. Gut, 2014. 63(10): p. 1550-9. 
80. Wang, G., Maier, S. E., Lo, L. F., Maier, G., Dosi, S., & Maier, R. J.  , 
Peptidoglycan deacetylation in Helicobacter pylori contributes to bacterial 
survival by mitigating host immune responses. Infection and immunity. 2010. 
78(11): p. 4660-4666. 
81. Cullen, T.W., Giles, D. K., Wolf, L. N., Ecobichon, C., Boneca, I. G., & Trent, M. S. 
, 7(12), e1002454., Helicobacter pylori versus the host: remodeling of the 
bacterial outer membrane is required for survival in the gastric mucosa. PLoS 
Pathogens, 2011. 7(12). 
82. Thompson, L.J., et al., Chronic Helicobacter pylori infection with Sydney strain 1 
and a newly identified mouse-adapted strain (Sydney strain 2000) in C57BL/6 and 
BALB/c mice. Infection and immunity, 2004. 72(8): p. 4668-4679. 
83. Machado, A.M.D., et al., Helicobacter pylori infection induces genetic instability 
of nuclear and mitochondrial DNA in gastric cells. Clinical Cancer Research, 2009. 
15(9): p. 2995-3002. 
84. Sozzi, M., Crosatti, M., Kim, S. K., Romero, J., & Blaser, M. J., Heterogeneity of 
Helicobacter pylori cag genotypes in experimentally infected mice. FEMS 
microbiology letters, 2001. 203(1): p. 109-114. 
 85 
 
85. McGuckin, M.A., et al., Muc1 mucin limits both Helicobacter pylori colonization of 
the murine gastric mucosa and associated gastritis. Gastroenterology, 2007. 
133(4): p. 1210-1218. 
86. Turner, P.V., et al., Oral gavage in rats: Animal welfare evaluation. Journal of the 
American Association for Laboratory Animal Science: JAALAS, 2012. 51(1): p. 25. 
87. Anon. Mouse Husbandry, Breeding and Development. University of Carolina, Irvine, 
Transgenic Mouse Facility Guidelines.  [cited 2015 24 January]. 
88. Donnelly, T.M. The Merk Veterinary Manual. Gerbils 2011  [cited 2015 24 January]. 
89. Wang, X., et al., Development of high‐grade lymphoma in Helicobacter pylori‐
infected C57BL/6 mice. Apmis, 2000. 108(7‐8): p. 503-508. 
90. Anonymous. Giemsa for Helicobacter pylori. 1997; Available from: 
http://www.nottingham.ac.uk/pathology/protocols/giemshel.html. 
91. Schwint, O.A., et al., A modification of the staining technique of reticular fibres 
for image analysis of the cardiac collagen network. Cardiovascular Pathology, 
2004. 13(4): p. 213-220. 
92. Ramos-Vara, J. and M. Miller, When Tissue Antigens and Antibodies Get Along 
Revisiting the Technical Aspects of Immunohistochemistry—The Red, Brown, and 
Blue Technique. Veterinary Pathology Online, 2014. 51(1): p. 42-87. 
93. Rotimi, O., et al., Histological identification of Helicobacter pylori: comparison of 
staining methods. J Clin Pathol, 2000. 53(10): p. 756-9. 
94. Wang, X., et al., Infection of BALB/c A mice by spiral and coccoid forms of 
Helicobacter pylori. Journal of medical microbiology, 1997. 46(8): p. 657-663. 
95. Hausen, H.z., Infections Causing Human Cancer. 2006: Wiley-VCH. 
96. Ohno, T., et al., Effects of blood group antigen-binding adhesin expression during 
Helicobacter pylori infection of Mongolian gerbils. J Infect Dis, 2011. 203(5): p. 
726-35. 
97. Crawford, H.C., et al., Helicobacter pylori strain-selective induction of matrix 
metalloproteinase-7 in vitro and within gastric mucosa. Gastroenterology, 2003. 
125(4): p. 1125-1136. 
98. Leung, W.K., et al., Effects of Helicobacter pylori eradication on methylation 
status of E-cadherin gene in noncancerous stomach. Clinical cancer research, 
2006. 12(10): p. 3216-3221. 
99. Hitkova, I., et al., Caveolin-1 protects B6129 mice against Helicobacter pylori 
gastritis. PLoS pathogens, 2013. 9(4): p. e1003251. 
100. Yamaoka, Y., D.H. Kwon, and D.Y. Graham, A Mr 34,000 proinflammatory outer 
membrane protein (oipA) of Helicobacter pylori. Proceedings of the National 
Academy of Sciences, 2000. 97(13): p. 7533-7538. 
  
References 
86 
 
101. Croisier, F. and C. Jérôme, Chitosan-based biomaterials for tissue engineering. 
European Polymer Journal, 2013. 49(4): p. 780-792. 
102. Sinha, V., et al., Chitosan microspheres as a potential carrier for drugs. 
International Journal of Pharmaceutics, 2004. 274(1): p. 1-33. 
103. Jiang, T., et al., Micro-and nanofabrication of chitosan structures for 
regenerative engineering. Acta biomaterialia, 2014. 10(4): p. 1632-1645. 
104. Patel, M.P., R.R. Patel, and J.K. Patel, Chitosan mediated targeted drug delivery 
system: a review. Journal of Pharmacy & Pharmaceutical Sciences, 2010. 13(4): p. 
536-557. 
105. Dhawan, S., A.K. Singla, and V.R. Sinha, Evaluation of mucoadhesive properties of 
chitosan microspheres prepared by different methods. Aaps Pharmscitech, 2004. 
5(4): p. 122-128. 
106. Rajput, G., et al., Stomach-specific mucoadhesive microsphere as a controlled 
drug delivery system. Systematic Reviews in Pharmacy, 2010. 1(1): p. 70. 
107. Ko, J., et al., Preparation and characterization of chitosan microparticles 
intended for controlled drug delivery. International journal of pharmaceutics, 
2002. 249(1): p. 165-174. 
108. Dong, Y., et al., Scalable ionic gelation synthesis of chitosan nanoparticles for 
drug delivery in static mixers. Carbohydrate Polymers, 2013. 94(2): p. 940-945. 
109. Mi, F.-L., et al., Synthesis and characterization of biodegradable TPP/genipin co-
crosslinked chitosan gel beads. Polymer, 2003. 44(21): p. 6521-6530. 
110. Karnchanajindanun, J., M. Srisa-ard, and Y. Baimark, Genipin-cross-linked chitosan 
microspheres prepared by a water-in-oil emulsion solvent diffusion method for 
protein delivery. Carbohydrate Polymers, 2011. 85(3): p. 674-680. 
111. MARTINS, C., et al., Microspheres. 2013, Google Patents. 
112. Bastos, J., et al., Sociodemographic determinants of prevalence and incidence of 
Helicobacter pylori infection in Portuguese adults. Helicobacter, 2013. 18(6): p. 
413-422. 
113. Parreira, P., et al., Effect of surface chemistry on bacterial adhesion, viability, 
and morphology. Journal of Biomedical Materials Research Part A, 2011. 99(3): p. 
344-353. 
114.   ISO 10993-5. Biological evaluation of medical devices. Tests for in vitro 
cytotoxicity. 2009, Geneva: International Standards Organization. 
115. Peek, R.M., Helicobacter pylori infection and disease: from humans to animal 
models. Disease models & mechanisms, 2008. 1(1): p. 50-55. 
116. Chey, W.D., Management of Helicobacter pylori Infection. American Journal of 
Gastroenterology, 2007. 102: p. 1808–1825  
 87 
 
117. Fischbach, L.A., et al., Sources of variation of Helicobacter pylori treatment 
success in adults worldwide: a meta-analysis. Int J Epidemiol, 2002. 31(1): p. 128-
39. 
118. Vakil, N. and J. Connor, Helicobacter pylori eradication: equivalence trials and 
the optimal duration of therapy. Am J Gastroenterol, 2005. 100(8): p. 1702-3. 
119. Fuccio, L., et al., Meta-analysis: duration of first-line proton-pump inhibitor 
based triple therapy for Helicobacter pylori eradication. Ann Intern Med, 2007. 
147(8): p. 553-62. 
120. Sougioultzis, S., et al., Alterations in the Proliferating Compartment of Gastric 
Mucosa during Helicobacter Pylori Infection: The Putative Role of Epithelial Cells 
Expressing p27kip1. Mod Pathol, 0000. 16(11): p. 1076-1085. 
121. Joana Gomes, A.M., Valérie Michel, Inês F. Amado, Paulo Aranha, Rikke G. Ovesen, 
Hans C. B. Hansen, Fátima Gärtner, Celso A. Reis, and Eliette Touati, Pteridium 
aquilinum and Its Ptaquiloside Toxin Induce DNA Damage Response in Gastric 
Epithelial Cells, a Link With Gastric Carcinogenesis. Toxicological Sciences, 2012. 
126(1): p. 60-71. 
122. Dai, J., et al., Effects of polyunsaturated fatty acids on the growth of gastric 
cancer cells in vitro. Lipids Health Dis, 2013. 12: p. 71. 
123. in Technical files of research models: C57BL/6, C. River, Editor. 
124.    Fox, J. G., & Wang, T. C. (2007). Inflammation, atrophy, and gastric cancer.Journal 
of Clinical Investigation, 117(1), 60. 
125. Rangel, M., et al., Analysis of the Toxicity and Histopathology Induced by the Oral 
Administration of Pseudanabaena galeata and Geitlerinema splendidum 
(Cyanobacteria) Extracts to Mice. Marine drugs, 2014. 12(1): p. 508-524. 
 
  
  
88 
 
  
 89 
 
Appendix A 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
Figure A1. Preliminary results of Western Blot analysis of H. 
pylori B128 strain. Results reveal the presence of BabA adhesin 
for the several passages (P2, P3 and P4). 17875/Leb and 17876 
babA1A2 served, respectively, as positive and negative controls 
(unpublished work). 
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Appendix B 
The BSA calibration curve obtained for protein quantification is presented in Figure 
B1.  
 
Figure B1. BSA calibration curve for total protein quantification. x 
corresponds to the BSA concentration (µg/mL) and y is the optical 
density at 750nm. 
  
The equation obtained (presented in Figure B1) allowed the determination of the total 
protein concentration (Cprotein) of each sample, based on equation B1. 
 
𝐶𝑝𝑟𝑜𝑡𝑒𝑖𝑛 =
𝑂𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦−0.0922
0.0002
                                                                                   (B1) 
 
 Once determine the concentration of the extracts, and normalizing the amount of 
protein to load each lane (mprotein=25µg), the volume of protein (Vprotein) was determined 
using equation B2. 
 
𝑉𝑝𝑟𝑜𝑡𝑒𝑖𝑛(µ𝐿) =
𝑚𝑝𝑟𝑜𝑡𝑒𝑖𝑛(µ𝑔)
𝐶𝑝𝑟𝑜𝑡𝑒𝑖𝑛
× 103                                                                                    (B2) 
 
 
  
y = 0,0002x + 0,0922 
R² = 0,9973 
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Appendix C 
 
 
 
 
Figure C1. Normal weight variation (g) 
curve as a function of the age (weeks) of 
C56BL/6 mice. Values indicate the mean 
weight of mice (male or female) and the 
correspondent standard deviation. 
Retrieved from Charles River’s Technical 
file for C57BL/6 mice [123]. 
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Appendix D 
 
Figure D1. Histological progression of Helicobacter-induced gastric cancer in a mouse model. Normal: Histology of 
the body of the stomach. Acute gastritis: Infiltration of mucosal and submucosal lymphocytes with pockets of 
polymorphonuclear cells, accompanied by mild mucosal defects and edema. Chronic gastritis: Moderate to severe 
inflammation with marked epithelial defects including gland dilatation and mineralization. Atrophic gastritis: Chronic 
inflammation with focal fibrosis and complete loss of oxyntic parietal and chief cells. Intestinal metaplasia: Gastric 
epithelial metaplasia to an intestinal phenotype characterized by columnar elongation, mucous droplets occasionally 
forming goblet cells, and production of mixed acidic (blue, intestinal-type) and neutral (red, gastric-type) mucins as 
shown by pH 2.5 Alcian blue/PAS stain (inset). Dysplasia: High-grade glandular dysplasia characterized by irregular 
size and shape, infolding, branching and cell piling, and marked cellular and nuclear atypia. Cancer: Gastric 
intraepithelial neoplasia, here with intramucosal invasion (arrow), develops in H. pylori–infected wild-type B6129 
mice, as well as in certain genetically engineered models (124–126). Scale bars: 160 mm (first panel); 400 mm (second 
through fourth panels); 80 mm (fifth panel; inset, original magnification, ×400); 40 mm (sixth panel); 800 mm 
(seventh panel). Retrieved from Fox, J. et al. [124] 
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Figure D234. Histological sections of mice liver: (A) Hyperemia an proximity of the centrilobular 
vein (circles) and disorganization of the hepatic parenchyme; (B) Proximity of the centrilobular vein 
(circle) and disorganization of the hepatic parenchyme; (C) Necrosis (circle), vacuolization of liver 
cells (arrows), and disorganization of the hepatic parenchyme. Adapted from Rangel, M. et al. [124] 
 
